Thrive Zone Academy · Lesson 40 · Deep Dive

What role does cholesterol play in your cardiovascular health?

What you need to understand, which numbers count – and how to turn that into actions that fit into your everyday life. This article walks you through the topic in three steps: first the understanding, then your own situation, then the implementation. All central claims are backed by studies, systematic reviews and guidelines; my own assessments are marked as such. The number in square brackets leads to the source at the end.

Andreas Heumann · Pillar 2: Nutrition · 44 measures · over 200 references · updated October 13, 2026

Andreas explainsWhy I wrote this article

My own interest in this topic comes from personal experience. As some of you know, my diet as a teenager was far from healthy, and in my early twenties I had to change it drastically. I had, you could say, everything you can do without: an inflamed gut including Leaky Gut, stomach ulcers, Helicobacter, bloating, abdominal pain, diarrhea – and my blood sugar was at the limit as well. The reason was a mix of ignorance and stupidity, plus an outright addiction to sweets. Through years of Trial and Error I managed to turn things around; today I am almost symptom-free. That is also why I am so consistent with the way I eat now: I know what it is like when things go seriously wrong.

A little over a year ago I went through a very comprehensive – and very expensive – screening: microbiome analysis, all blood values, micronutrients, inflammation markers, diabetes markers, heavy metals and more. Everything. My cholesterol came back clearly elevated, which had never been the case before. That activated my research drive and led to a fine-tuning of my diet and my supplements – one year later I am back in the normal range.

One thing matters here: just because something lowered my cholesterol does not mean it will do the same for you. So writing down my own experience would have been too little. I took the time to work through the whole topic: this article rests on scientifically established results, and what worked for me appears where the studies back it up. That way you, too, can lower your cardiovascular risk as far as possible. One thing you will notice along the way: in the body, everything is connected. Diet, physical activity, sleep, stress and environment act together, and I try here, as far as I can, to draw a complete picture.

Important: What you read here is my research and my experience; it does not replace medical advice. Because the topic matters, I recommend you do what I did and start with a complete medical screening. Then you know where you stand and can approach the topic from an informed position – with medical support if in doubt, and at the very least by checking it against your numbers. If you would like a contact from my network for that, get in touch with me.

How to read the numbers in this article. mg/dL is the unit for blood lipids that German laboratories usually use; some report mmol/L (1 mmol/L LDL = 39 mg/dL). RR, OR, HR (relative risk, odds ratio, hazard ratio) are comparison figures between two groups: 1.0 means no difference, values below 1 mean fewer, values above 1 mean more. For relative risk, 0.8 means exactly 20% fewer events; for odds ratio and hazard ratio this is an approximation that fits well for rare events and deviates somewhat for frequent events. n is the number of participants. An RCT (randomized controlled trial) assigns participants to the intervention and the control group by lot – the most reliable study type when it comes to cause and effect. A meta-analysis combines many studies into one figure. An observational study (cohort) follows people over years without intervening; it shows associations rather than causes. A Mendelian randomization uses randomly inherited gene variants as a natural experiment to separate cause from mere association. GRADE (a rating system for study quality) high, moderate or low rates how reliable the overall body of evidence is. n. s. means: falls short of statistical significance. The technical terms are explained in the glossary at the end.

Part 1

Understand

What cholesterol is, what the numbers mean, and which of them matter.

1 · Why cholesterol is one of the most important markers for your heart

Cardiovascular disease is the leading cause of death in Germany: in 2024, around 339,000 people died of it, about one third of all deaths [215]. Most of these deaths trace back to deposits in the blood vessels, and LDL cholesterol is the best-documented cause of those deposits: more than 200 studies with over two million people reach this conclusion [3]. A high LDL level is therefore more than a warning sign – it is part of the cause, and it can be changed. That makes it one of the most important numbers you should know.

At the same time, LDL is one of several factors. Blood pressure, smoking, belly fat and insulin act alongside it, and some numbers that appear on every lab report tell you less than their reputation suggests. That is why this article follows the same order I use in coaching: first you understand what the numbers mean and how they are connected. Then you look at where you stand – and that takes a measurement. Only then comes the part that counts: what you change in everyday life. A measure that cannot be translated into a concrete action has no value to me.

Nine things to understand before you change anything

Cholesterol is building material

It is in every cell membrane and serves as raw material for testosterone, estrogen, cortisol, bile acids and vitamin D. Your body makes most of it itself (on the order of 700–900 mg per day versus 300–500 mg from food); if you eat more of it, the liver produces less.

[1][2] · review-based approximation

Cholesterol travels in transport particles

Cholesterol is a fat and does not dissolve in blood. Your body therefore packages it into transport particles, the lipoproteins. LDL (low-density lipoprotein) carries cholesterol from the liver out into the body – it is the delivery van. HDL (high-density lipoprotein) collects excess cholesterol again – the pickup service. When your doctor talks about your “LDL level,” they mean the amount of cholesterol currently traveling in LDL particles. Triglycerides are a second type of fat in the blood, your storage fat; they travel in their own particles (VLDL, very-low-density lipoprotein), which turn into LDL along the way.

[2] · review

LDL causes the deposits in the blood vessels

More than 200 studies with over 2 million people – observational studies, genetic studies and drug trials – reach the same conclusion: LDL particles lodge in the vessel wall and cause the deposits, the plaques (the medical term for the disease is atherosclerosis). When a plaque ruptures, a clot forms – that is the heart attack or the stroke. Two things count here: how high your LDL is and how long it has been high. Whoever lowers it early lowers it for longer.

[3] · consensus statement of the European Atherosclerosis Society (EAS)

ApoB counts the particles

ApoB (apolipoprotein B) is a protein that sits on the outside of every particle capable of carrying cholesterol into the vessel wall – on LDL and its relatives. Each of these particles carries exactly one ApoB molecule. The ApoB value therefore counts the particles, while the LDL value only measures their cholesterol cargo. In an analysis of almost 390,000 people, in the end only ApoB was linked to heart attack; LDL, non-HDL (total cholesterol minus the HDL fraction) and triglycerides had no independent predictive value alongside it. Have ApoB measured as well – it costs little, and you do not need to be fasting for it.

[4][5][13]

HDL, the “good cholesterol,” describes your metabolism

HDL (high-density lipoprotein) is the particle that carries excess cholesterol from the body back to the liver. People with high HDL have fewer heart attacks, which is why it is popularly called “good cholesterol,” and many try to raise it deliberately. The assumption behind this – more HDL protects – has turned out to be wrong over the past 15 years. People with a gene variant that raises their HDL for life have just as many heart attacks as everyone else (odds ratio 0.99; a value of 1.0 means no difference). And three drugs that raised HDL by 30 to 130 % produced no confirmed reduction in heart attacks in large trials – one of them increased mortality. A high HDL is therefore a sign of a healthy metabolism; the protection comes from the metabolism itself. A low HDL tells you that something is off there, usually too little movement, too much belly fat or triglycerides that are too high. You treat that, and HDL rises on its own.

[6][7] · Mendelian randomization + RCTs

Triglycerides respond quickly to lifestyle

Triglycerides respond within weeks to sugar, alcohol, weight and exercise. For heart attack risk, lowering triglycerides only pays off, according to the evidence so far, when the number of ApoB particles drops with it. (Very high triglycerides, from about 500 mg/dL, are a separate matter: there the concern is the risk of pancreatitis, and that belongs with your doctor.) The drug pemafibrate lowered triglycerides by 26 %, while ApoB particles rose by 4.8 % – and cardiovascular events remained statistically unchanged (HR 1.03). The cholesterol in triglyceride-rich remnant particles (remnant cholesterol), on the other hand, is a cause in its own right (OR 2.8 per mmol/L).

[8][9][15] · RCT + Mendelian randomization

Lp(a): measure it once in your life

Lipoprotein(a), Lp(a) for short, is a type of LDL particle with an additional protein attachment; it lodges in the vessel wall especially easily. Your Lp(a) level is more than 90 % genetically determined. Diet changes it very little – less saturated fat even raises it by 10 to 15 %, and statins, the usual cholesterol medications, barely lower it either. If it is high (above 50 mg/dL), you go about everything else more consistently: LDL, blood pressure, smoking. That is what you can do, and it works.

[10][14][63]

Eggs are a secondary tap

Per 100 mg of dietary cholesterol, LDL rises by 1.9 to 4.6 mg/dL; one egg contains around 190 mg. The more you already eat, the smaller the increment. Up to one egg per day, heart attack risk is unchanged in large population studies (RR 0.99). In type 2 diabetes, risk was elevated in the group with the highest egg consumption (RR 1.54) – these are observational data. The main tap is the saturated fat on your plate; the egg is the secondary tap.

[16][17]

Four things put a load on your blood vessels

The number of ApoB particles and how long it stays high · blood pressure · metabolism (belly fat, insulin, inflammation) · and how stable the plaques are (smoking, clotting). LDL is causal, blood pressure is causal, smoking is causal. The measures below address all four.

[3][46] · consensus + meta-analysis

2 · Numbers that can improve without doing anything for you Four examples where the blood value got better and heart attacks stayed the same

Two terms that come up again and again in this article: A marker is a blood value that tells you something about your risk – people with an unfavorable value have heart attacks more often. A lever is something you change – and your risk drops. LDL is both: a high value signals the risk, and whoever lowers it has fewer heart attacks. The four values in this section are markers only. They indicate that something in your metabolism is off. Three of them were improved with medications or vitamins in large trials, and the number of heart attacks stayed the same – because the cause lies elsewhere. For the fourth, TMAO, no such trial exists yet.

HDL – the “good cholesterol”

Four drugs were developed to raise HDL; the idea was that more “good cholesterol” protects against heart attacks. All four were tested in trials with tens of thousands of participants. Torcetrapib raised HDL by 72% and increased mortality (HR 1.58). Dalcetrapib (+31–40%) and evacetrapib (+133%): no effect. Anacetrapib (+104% HDL) worked – and at the same time lowered non-HDL by 18%. The benefit came from the reduction in ApoB particles.

[6][7] · RCTs, n = 30,449 (REVEAL)

Triglycerides

High triglycerides go together with more heart attacks. The open question was whether lowering triglycerides on its own protects you. The drug pemafibrate lowered triglycerides by 26% and remnant cholesterol by 26%; the number of ApoB particles rose by 4.8%, and heart attacks stayed the same (HR 1.03). Genetic studies confirm this: gene variants that lower triglycerides and gene variants that lower LDL protect equally well – per ApoB particle removed.

[8][9] · RCT + Mendelian randomization, n = 654,783

Homocysteine

Homocysteine is an amino acid produced during protein metabolism; a high value goes together with more heart attacks. Folic acid, B6 and B12 lower it reliably. Heart attacks: RR 1.02 (12 studies, n = 46,699, high quality). Strokes: RR 0.90, carried by one Chinese mega-trial. A true B12 or folate deficiency still needs to be treated.

[94] · Cochrane, 15 RCTs, n = 71,422

TMAO

TMAO (trimethylamine N-oxide) is a substance that gut bacteria produce from choline and carnitine – both are found in red meat and eggs. Higher TMAO values are seen in people with heart disease. The studies behind this, however, come from high-risk groups and account for other influencing factors insufficiently; long-term studies in healthy people are missing entirely, and no study has tested whether lowering TMAO achieves anything. Confidence in the evidence: “critically low”. TMAO is currently unsuitable as a basis for action.

[95] · Review of 27 meta-analyses

Andreas explainsIn short

Take one thing from Part 1: LDL and ApoB are the values that do the damage in your blood vessels. HDL, triglycerides and the other values show you how your metabolism is running – even when they look good, they offer no protection against a heart attack.

That is exactly where it started for me: my value was high, and before I changed anything, I wanted to understand what it meant. So if someone tells you your HDL is fine and therefore everything is in order – now you know why that falls short.

Part 2

Know where you stand

A measurement is the only way to find out where you stand. This section explains what the numbers mean and when your doctor comes before any action on your part.

3 · Your numbers: what to have measured and what they mean Your LDL target depends on your cardiovascular risk [13][63]

Most people start looking into cholesterol because one number stood out. If you have no current numbers yet: have your doctor (GP) run a lipid panel – total cholesterol, LDL, HDL and triglycerides – plus ApoB. Lp(a) is measured once in your lifetime, because it barely changes (see Part 1). ApoB and Lp(a) are often left out of the standard blood draw; ask for them specifically. LDL and ApoB can be measured without fasting [13]. With the numbers in hand, read the following table.

The categories in the table describe your overall risk of having a heart attack or stroke. The higher that risk, the lower the target value. Someone who has already had a heart attack should therefore be below 55 mg/dL; at low overall risk, below 116 mg/dL serves as the guiding target. The examples in the column “Who falls into this category” are incomplete: a single risk factor such as smoking does not automatically place you in a category, age and blood pressure level play a part, and with diabetes the duration and accompanying conditions count. Your doctor assigns the category.

Your cardiovascular risk	Who falls into this category	LDL target	Secondary targets ApoB / non-HDL
Very high risk	Existing vascular disease (heart attack, stroke, stent, bypass) · diabetes with organ damage · severe kidney disease	< 55 mg/dL (1.4 mmol/L) and reduce by at least half	ApoB < 65 · non-HDL < 85 mg/dL
High risk	Familial hypercholesterolemia (the inherited form, see Section 4) · LDL of 190 mg/dL or higher · blood pressure of 180/110 or higher · moderate kidney disease · diabetes without organ damage	< 70 mg/dL (1.8 mmol/L) and reduce by at least half	ApoB < 80 · non-HDL < 100 mg/dL
Moderate risk	Risk factors without a diagnosis – smoking, excess weight, high blood pressure, little physical activity, early heart attacks in the family	< 100 mg/dL (2.6 mmol/L)	ApoB < 100 · non-HDL < 130 mg/dL
Low risk	Example: younger, nonsmoker, normal blood pressure, no diabetes, no family history – according to a risk calculator	< 116 mg/dL (3.0 mmol/L)	ApoB / non-HDL: no secondary target

“Reduce by at least half” means the stricter of the two requirements applies. A starting LDL of 100 in the “high” category → target 50. For people who appear healthy, your doctor calculates the category with a risk calculator (SCORE2) from age, sex, blood pressure, smoking and cholesterol; with diabetes, known vascular disease or familial hypercholesterolemia the category applies directly, without a calculator. The table is a guide. Non-HDL is total cholesterol minus HDL, in other words everything that can form deposits. At moderate risk and when the treatment decision is unclear, a coronary artery calcium score (CAC, a computed tomography scan without contrast agent) can add to the assessment; the 2025 guideline lists it as a risk modifier (class IIa) [63]. A score of zero still leaves deposits possible and leaves any indication for treatment that exists on other grounds in place. The 2025 Focused Update confirmed the target values unchanged and added Lp(a) > 50 mg/dL as a risk modifier [63]. What you should have measured: the lipid panel (total cholesterol, LDL, HDL, triglycerides) plus ApoB, Lp(a) once, and in addition TSH (thyroid-stimulating hormone, the thyroid marker), HbA1c (glycated hemoglobin, the long-term blood sugar marker) and blood pressure at home. Routine checks require no fasting; with strongly elevated triglycerides (above 440 mg/dL) a repeat measurement in the fasting state can be useful [18].

Andreas explainsIn short

I made my own screening very comprehensive. That level is optional, but four numbers are the minimum: LDL, HDL, triglycerides and ApoB – plus Lp(a) once in your lifetime. Ask for your results as actual numbers, and ask your doctor which risk category you fall into.

A number gives you a target, and a target gives you an action. Everything that follows builds on that.

4 · When to see your doctor first – and what needs checking if your LDL stays high Some things you clarify before you start; others once your numbers barely respond after consistent effort.

See your doctor first – before you start, if any of these applies to you: LDL of 190 mg/dL or above · heart attack, stroke, stent, bypass or known coronary heart disease (CHD, narrowed coronary arteries) · early cardiac events in the family · high Lp(a) · blood pressure repeatedly at or above 140/90 · diabetes or kidney disease · LDL stays high despite consistent effort. Diet, training and lifestyle remain important in all of these cases – on their own, though, they usually fall short of the target value. In people with existing heart disease, exercise-based rehabilitation lowers heart attacks by 28% (RR 0.72, GRADE high) [66].

If your LDL barely responds after about twelve weeks of consistent effort, these causes need to be checked:

Thyroid (TSH)

An underactive thyroid slows your metabolism, including the breakdown of LDL in the liver. It is the most common cause of high LDL outside of diet and genetic predisposition. A blood test finds it: TSH is the hormone that controls the thyroid, and its level rises when the thyroid is underactive. In overt hypothyroidism, treatment lowers LDL by around 41 mg/dL; in subclinical hypothyroidism, by about 8–9 mg/dL. Signs: fatigue, sensitivity to cold, weight gain, dry skin, unexplained high LDL.

[13][60][61] · guideline + meta-analyses

Familial hypercholesterolemia

An inherited defect in LDL clearance: the liver takes up too little LDL from the blood, and LDL is high from birth. It affects around 1 in 313 people and usually goes undetected. Signs: LDL of 190 mg/dL or above since a young age, early heart attacks in the family, cholesterol deposits on the tendons (tendon xanthomas); diet and lifestyle have only a limited effect. Diet remains important; a medication is usually needed in addition.

[62] · meta-analysis, 10.9 million people

Menopause

Total cholesterol, LDL and ApoB rise measurably in the year around the final menstrual period – independent of chronological aging. The cause is the hormonal shift. Check your numbers actively around menopause, take strength training and protein seriously, and keep waist circumference and blood pressure in view. Hormone therapy treats menopausal symptoms; as protection against heart attack, the US Preventive Services Task Force considers it unsuitable [194].

[64][65] · SWAN cohort

Medications and other causes

A specific kidney disease (nephrotic syndrome), liver and gallbladder problems, diabetes, corticosteroids, retinoids, certain hormones and HIV medications can shift lipids. If your numbers fail to match what you have put into practice, look for the cause together with your doctor.

[13] · guideline of the European cardiology and atherosclerosis societies (ESC/EAS)

Part 3

Act

What is proven to work, in what order – and how you turn it into habits that last.

5 · What works: 44 measures, ranked by benefit and how well they fit into everyday life 44 entries in five groups. The order within a group is my professional weighting based on effect size, quality of evidence and feasibility; the “Effect” column states in each case what the number refers to: LDL, blood pressure, events or an observed association. Effect sizes are averages across studies – your response may differ.

How to convert every number here: In the large statin trials (26 trials, 170,000 people, five years on average), about 39 mg/dL (1 mmol/L) less LDL went along with roughly 20–22 % fewer major cardiovascular events and about 10 % fewer deaths [11]. That is a relative reduction: someone with a low baseline risk gains less in absolute terms than someone with a high one. Ten milligrams less corresponds, in this calculation, to roughly 5–6 % fewer events. An analysis of 49 trials with more than 300,000 people found the same benefit per milligram lowered for measures that, like statins, work through the liver – among them dietary changes, ezetimibe and bile acid sequestrants [12]. For individual foods or supplements, direct evidence for this is still missing; the conversion is an approximation that shows the order of magnitude of a lever. The difference between diet and medication lies in the size of the reduction.

Andreas explainsIn short

The order here is my weighting, and it rests on three criteria: how large the effect is, how well it is proven – and whether you will still be doing it in four weeks. In practice, the third criterion is the one that decides most often. Complexity makes people quit.

For me it was a year of fine-tuning diet and supplements, and throughout I only ever adjusted a few variables at a time. Start with Group A. If you change only three things, make it three from there.

The five groups: A lowers LDL the most, B lowers it further, C covers dietary patterns and foods that mainly prevent heart attacks and strokes (and barely change LDL), D is blood pressure, quitting smoking, movement and fitness; E is sleep, mental health and environment. If you change only three things, take them from A – and if you smoke or have high blood pressure, start in D.

Group A · The foundation for LDL and ApoB

Largest effect on LDL, solid evidence, doable in everyday life

If you change only three things, make it three from this list.

#	Lever	Effect	Evidence	Source
1	Portfolio principle: all dietary levers togetherFour food groups that each lower LDL by a different route, combined every day – hence the name portfolio: nuts, plant protein (legumes, soy), soluble fiber (oats, psyllium) and plant sterols (plant compounds that resemble cholesterol; more on these under Lever 7). Each measure on its own lowers LDL only a little; together, in a six-month study with participants who cooked at home, they produced a 13 % reduction. The participants received only two counseling appointments in six months for this – so the principle can be put into practice without close supervision.	LDL −13 % net ≈ −10 percentage points vs. control; meta-analysis of 7 controlled trials against a comparison diet: −17 %	RCT n = 345GRADE highmoderate effort	[19][20]
2	Swap saturated fat for unsaturatedSaturated fat is the fat that is solid at room temperature; it is found mainly in butter, processed meat, cheese, cream and coconut oil. It slows the uptake of LDL into the liver, so more LDL stays in the blood. The swap: butter, processed meat, cream, coconut oil → olive oil, canola oil, nuts, fatty fish. The calorie amount stays the same; only the type of fat changes. Every percent of your daily calories that you shift from saturated to polyunsaturated fat lowers LDL by 2.1 mg/dL. Replacing the butter on your bread, the fat you fry with and the processed meat gets you to about five percent – roughly 10 mg/dL. Butter is the largest single item: the same amount of saturated fat from cheese raises LDL by 6–8 mg/dL less than from butter, probably because of the calcium, protein and fermentation in cheese. Unsaturated fats remain the better choice – cheese is just the lesser evil.	LDL ≈ −10 mg/dL events −17 % (RR 0.83) over ≥ 2 years	84 studiesevent evidence, Cochranelow effort	[21][22][124][125]
3	Psyllium husk, 10 g daily10 g is roughly two heaped teaspoons, in water, quark or muesli; best to weigh it out once. Psyllium binds bile acids in the gut; the liver has to make new ones and takes the cholesterol for that from the LDL in the blood. Among the fibers in this document, psyllium has the largest ApoB effect proven in meta-analyses. Always take it with a large glass of water; with medications, keep the interval stated in the package insert, usually one to two hours.	LDL −13 mg/dL ApoB −5 mg/dL (−0.05 g/L)	28 RCTsApoB: GRADE highvery low effort	[23]
4	Oats: 3 g beta-glucan dailyBeta-glucan is the soluble fiber in oats; depending on the product, 3 g is contained in about 70–80 g of rolled oats – one serving of porridge or overnight oats. Above 3 g per day, the reduction seen in the studies levels off.	LDL −7 to −10 mg/dL ApoB −3 mg/dL (−0.03 g/L)	28 + 58 RCTsEU health claimvery low effort	[24][25]
5	Nuts, 30–60 g dailyThat is one to two handfuls, depending on your hand. The dose is what counts; any variety works – almonds, walnuts, hazelnuts, pistachios. From 60 g per day upward, the effect per gram is larger than at smaller amounts. Unsalted and unsweetened.	LDL −4.8 mg/dL per 28 g ApoB −3.7 mg/dL	61 studiesvery low effort	[26]
6	Lose weight – if you are carrying extraPer kilogram lost, LDL drops by about 1 mg/dL. The larger benefit lies in insulin, blood pressure, belly fat and triglycerides. While you are losing weight, HDL drops temporarily; it rises only once your weight is stable. A reading taken in the middle of weight loss can therefore look worse for HDL than the value after a maintenance phase; the timing of the check-ups themselves depends on your baseline value and risk, which your doctor sets. Repeated losing and regaining (yo-yo dieting) goes along with more cardiovascular disease in observational studies – an argument for slow, stable weight loss; whether the yo-yo pattern itself is the cause remains open.	LDL −0.8 to −1.3 mg/dL per kg TG −1.3 to −4 mg/dL per kg	70 + 73 studieshigh effortaffects everything	[27][28][198]

Group B · More LDL-lowering levers

Proven, but smaller or with a condition attached

These measures lower LDL further; whether that is enough for your target depends on your starting value, your target and how you respond.

#	Lever	Effect	Evidence	Source
7	Plant sterols (phytosterols), 2 g dailyPlant sterols resemble cholesterol and compete with it for absorption sites in the gut. The reduction is a percentage: at an LDL of 150, 8.8% is about 13 mg/dL. Up to about 3 g per day, the effect rises to around 12%. Reaching 2 g takes fortified products or a supplement; regular foods alone fall short. The LDL reduction is proven; whether it leads to fewer heart attacks has never been studied directly. Contraindicated in sitosterolemia, a rare hereditary disorder.	LDL −8.8% (at 2.15 g) ≈ −13 mg/dL at LDL 150	84 + 124 studiesEU claim (risk factor)product required	[29][30][31]
8	Eating plant-based (vegetarian or vegan)Switching from a mixed diet to a plant-based diet lowers LDL and ApoB in randomized trials. Triglycerides stay the same; HDL drops slightly (by 3–4 mg/dL). The effect overlaps with Lever 2: if you have already replaced butter, processed meat and cream, you already have part of this. Plant-based saturated fats (coconut oil, palm oil) still count as saturated fat.	LDL −12 mg/dL ApoB −13 mg/dL	30 RCTslowers ApoBhigh effort	[101][102][103]
9	Legumes, one serving (~130 g cooked) dailyLentils, beans, chickpeas. Satiety, fiber, plant protein – and they often replace meat and processed-meat dishes high in saturated fat. Whether they also lower ApoB remains unproven.	LDL −6.6 mg/dL	26 RCTslow effort	[32]
10	Avocado and ground flaxseedBoth lower LDL by about 6 mg/dL. Avocado works best where it replaces butter, cheese or processed meat – on bread, in a salad; in a cohort of 110,000 people, this substitution was associated with 16–22% less cardiovascular disease. With flaxseed, the whole ground seed is what works (fiber and lignans, a specific group of plant compounds); flaxseed oil capsules do not lower LDL in the same studies. Flaxseed also lowers blood pressure by about 3/2.5 mmHg. Chia seeds are a similar source of fiber, but the evidence for an LDL effect there is inconsistent.	LDL ≈ −6 mg/dL each	RCT meta-analyseslow effort	[119][120][121][122][140]
11	Soy protein, ~25 g dailyTofu, tempeh, soy milk, edamame. A small, reliable contribution – above all as a replacement for fatty meat.	LDL −4.8 mg/dL (≈ 3–4%)	46 studieslow effort	[33]
12	Filter your coffee through paperCafestol, a compound in coffee oil, raises LDL; a paper filter holds it back. French press, Turkish, boiled, espresso: the cafestol ends up in the cup. In a small study, 61–64 mg of cafestol per day (≈ 8–9 cups of Scandinavian boiled coffee) raised LDL by 22 mg/dL. The effect depends on the amount; at two cups a day it is correspondingly smaller.	depends on consumption conservatively −5 mg/dL	study n = 10zero effort	[34][35]
13	Cut back on sugar and alcoholMore sugar raises triglycerides and LDL, even when weight stays the same. Fructose (fruit sugar) raises triglycerides only when it comes as extra calories; when it replaces other carbohydrates at the same calorie intake, the values stay the same. Alcohol (30 g per day, about three glasses of wine) raises HDL by 4 mg/dL and triglycerides by 5.7 mg/dL. The HDL increase brings no benefit, as described in Part 1. Genetic studies show that less alcohol lowers heart risk in every consumption group, including moderate drinkers.	TG −10 · LDL −4.6 mg/dL	39 RCTs (sugar)MR n = 261,991 (alcohol)	[36][37][38][39]
14	Probiotic foods and supplementsProbiotics are live bacteria that you take deliberately – as a supplement or in foods such as certain yogurts. Specific bacterial strains (in the studies mainly species of the genus Lactobacillus, such as L. plantarum and L. reuteri) lower LDL by a consistent 7–9 mg/dL across three meta-analyses; the meta-analyses partly overlap in the studies they include. The effect depends on the specific strain, the dose and the product; “yogurt in general” is a different thing. Heart attack outcomes have never been studied.	LDL −7 to −9 mg/dL	39 + 15 RCTsstrain-dependent	[132][133][208]
15	Intermittent fasting and eating windowsIntermittent fasting means eating only within a fixed time window, for example eight hours a day, or eating very little on certain days. Compared with no diet, intermittent fasting lowers LDL by about 6 mg/dL. Compared with ordinary calorie restriction without fasting, the eating window adds nothing further at the same calorie intake – for LDL, weight or any other value. The benefit therefore comes through weight (Lever 6). Study quality is mostly low, and several analyses report a loss of muscle mass. Skipping breakfast is associated with more cardiovascular disease in observational studies; because breakfast skippers smoke and drink more often, this allows no conclusion about fasting itself. A ketogenic diet (very few carbohydrates, very much fat) raises LDL: by about 5 mg/dL in people with overweight, and in three small studies of normal-weight people by around 40 mg/dL, with ApoB up by 35 mg/dL.	LDL −6 mg/dL vs. no diet ±0 vs. same calories	34 studieslow evidenceworks through weight	[104][105][106][107][108][109]

Group C · Dietary patterns and foods with event or blood pressure evidence

Linked to fewer heart attacks and strokes – they barely change LDL

This section covers what whole dietary patterns and individual foods have done in studies with hard endpoints (heart attack, stroke, death). Most of these data are observational, from large population studies; they show associations rather than causes. Exceptions with randomized trials are marked.

#	Lever	Effect	Evidence	Source
16	Potassium salt as a replacement for regular saltRegular salt is sodium chloride, and sodium raises blood pressure. Potassium salt replaces part of the sodium with potassium, which lowers blood pressure. A salt that is one quarter potassium chloride (sold as "potassium salt" or "reduced-sodium salt") lowers blood pressure by about 4.6/1.6 mmHg. In a randomized trial with 21,000 people over almost five years, it produced 14% fewer strokes, 13% fewer cardiac events and 12% fewer deaths – one of the few nutrition studies of any kind with hard endpoints. The participants were older Chinese adults at high risk with very high salt intake; the blood pressure effect, however, is consistent across 21 studies and all age groups. Important: If you have reduced kidney function or take blood pressure medications that keep potassium in the body (ACE inhibitors, sartans, potassium-sparing diuretics), talk to your doctor first [212].	Stroke −14% · Death −12% Blood pressure −4.6/−1.6 mmHg	RCT n = 20,995event evidencezero effort	[130][131]
17	Total fiber: 25–29 g per dayFiber is the part of plants that the small intestine does not digest. The number here is the umbrella figure covering oats, psyllium, whole grains, legumes, fruit and vegetables. People in this range have 15–30% fewer heart attacks, strokes and deaths than people who eat little fiber; more than 29 g appears to be even more favorable. In randomized trials, more fiber lowers blood pressure, cholesterol and body weight. Half of the people in Germany eat less than 18 g (women) or 19 g (men) per day [211].	Events and death −15 to −30%	185 cohorts + 58 RCTsGRADE moderate	[205]
18	Mediterranean dietary patternOlive oil as the main fat, plenty of vegetables, legumes, nuts, whole grains, fish, little red meat and few sweets. In the Spanish PREDIMED trial (7,400 people at high risk, aged 55–80), this pattern produced 40% fewer strokes and 30% fewer major cardiac events. Blood pressure drops by about 3/2 mmHg, LDL by only about 6 mg/dL. The pattern overlaps with levers 1, 2, 5 and 9 – if you put those into practice, you are already eating largely Mediterranean.	Stroke −40% Blood pressure −3/−2 · LDL −6 mg/dL	RCT n = 7,447 + 30 RCTsevent evidence	[202][203]
19	Fruit and vegetables, up to 800 g per dayFor every additional 200 g per day, the risk of coronary heart disease was 8% lower, the risk of stroke 16% lower and the risk of death 10% lower; the association holds up to about 800 g. Apples and pears, citrus fruit, green leafy vegetables and cruciferous vegetables stand out. Observational data from 95 studies.	per 200 g: stroke −16%	95 cohortsobservational	[129]
20	Whole grains, three servings per day90 g of whole grains per day (three slices of whole-grain bread, or a serving of oatmeal plus whole-grain pasta) is associated with 19% less coronary heart disease and 17% fewer deaths. LDL drops slightly (−3.5 mg/dL), most with whole-grain oats – this overlaps with lever 4.	coronary heart disease −19% LDL −3.5 mg/dL	45 cohorts24 RCTs (LDL)	[117][118]
21	Olive oil as a replacement for butter and margarinePeople who use more than half a tablespoon of olive oil a day have 19% less cardiovascular death in cohorts of 90,000 people; replacing 10 g of butter, margarine or dairy fat with olive oil was associated with an 8–34% lower risk of death. Other vegetable oils performed similarly. On its own, olive oil barely changes LDL – the benefit comes from the replacement (lever 2).	Cardiovascular death −19% LDL ±0	cohorts n = 92,383observational	[114][115][116]
22	Fatty fish, two servings per weekSalmon, mackerel, herring, sardines. Two to four fish meals per week are associated with about 20% less death from coronary heart disease; in the data, more adds nothing further, and in Western countries the association is weaker than in Asia. Fish has no effect on LDL. Fish oil capsules are a different matter – see Supplements.	Cardiac death −20% LDL ±0	17 cohortsobservational	[123]
23	Cut back on processed meatSausage, ham, bacon, salami. For every 50 g per day, the risk of coronary heart disease rises by 27% and the risk of stroke by 17% (observational). Unprocessed red meat has a weaker effect (+15% per 100 g), and the evidence there is uncertain; one large review rates the benefit of eating less red meat as "very small." The difference probably comes down to salt and curing agents: on average, processed meat contains four times as much salt and 50% more nitrate curing agents as unprocessed meat, with a similar saturated fat content [214].	per 50 g/day: coronary heart disease +27%	cohort meta-analysesobservational	[126][127]
24	Cut back on ultra-processed foodsReady meals, soft drinks, snacks, sausage, industrial baked goods. In observational studies, people who eat a high share of such products have a 50% higher risk of dying from cardiovascular disease. The data quality is low because the rest of the lifestyle plays a part; the direction is consistent across 45 analyses with almost 10 million people.	Cardiovascular death +50% with high intake	review, n ≈ 9.9 millionGRADE very low	[128]
25	Tea, hibiscus, pomegranateSmall, proven blood pressure effects: black and green tea as a beverage lower blood pressure by about 1.4–1.8 mmHg. Hibiscus tea lowers it by about 7/4 mmHg in people with elevated blood pressure, though the studies are small and inconsistent. Pomegranate juice lowers blood pressure by about 5/2 mmHg, though it comes with sugar and leaves LDL unchanged.	Blood pressure −1.4 to −7 mmHg	RCT meta-analysessmall, inconsistent	[134][135][136][137]

Group D · Blood pressure, movement, fitness

Large influence on cardiovascular risk, small influence on LDL

These measures have little effect on LDL. For the risk of having a heart attack or stroke, they are among the most effective of all. This is where the two measures with the largest proven benefit sit: lowering blood pressure and quitting smoking.

#	Lever	Effect	Evidence	Source
26	Lower your blood pressure if it is elevatedHigh blood pressure puts mechanical strain on the vessel wall and, alongside LDL, is the second established cause of heart attack and stroke; from 140/90 mmHg it counts as elevated. Lowering it is the measure with the largest proven benefit for your blood vessels. What lowers blood pressure in the diet: the DASH pattern (Dietary Approaches to Stop Hypertension – an eating pattern developed to counter high blood pressure: plenty of vegetables, fruit, legumes, whole grains, low-fat dairy) lowers it by 5.2/2.6 mmHg. 4–6 g less salt per day lowers it by 4.2/2.1 mmHg, in people with high blood pressure by 5.4. More potassium from potatoes, beans, vegetables and fruit lowers it by 4.5 mmHg in people with high blood pressure; for potassium salt see Lever 16. Nitrate from beetroot and leafy greens (a plant compound the body uses to make nitric oxide, which widens blood vessels) lowers the upper value by 4.4 mmHg, measured in short-term studies. Cocoa with a high cocoa content lowers it by 1.8/1.8 mmHg, in people with high blood pressure by 4; in a study of 21,000 people over 60, cocoa extract lowered cardiovascular death by 27%, though that was a secondary endpoint. Aged garlic extract lowers it by about 8/5 mmHg in people with high blood pressure, and hardly at all when blood pressure is normal.	per −10 mmHg: events −20%, mortality −13%	123 RCTs, n = 613,815event evidence	[46][47][48][49][50][51][148][204]
27	Quitting smokingSmoking, like LDL and blood pressure, is an established cause of heart attacks (Part 1, last card). Quitting has little effect on blood lipids: HDL rises by around 3.9 mg/dL, LDL stays unchanged – even when 4.6 kg come on in the first year. The large benefit arises elsewhere: at the inner vessel wall, in clotting tendency, in inflammation and oxidation. So the benefit for the heart runs almost entirely outside the blood lipids.	HDL +3.9 mg/dL · LDL ±0	27 studies + RCT n = 1,504largest single benefit	[52][53]
28	Build fitness (endurance capacity)Endurance capacity, measured as maximal oxygen uptake (VO₂max) or in METs (multiples of resting metabolic rate), is one of the strongest predictors of life expectancy. For each additional MET, the risk of cardiovascular events in cohorts was 15% lower. Those are comparisons between people with different fitness levels; how much of that a training-induced gain in fitness delivers has not been measured directly this way. People with low fitness have a 1.6- to 5-fold higher risk of death than fit people; in a clinical study of 122,000 people, low fitness weighed as heavily as smoking or diabetes, and there was no upper limit beyond which more fitness stopped paying off. Two to four hours of training per week are enough for measurable gains.	per MET: events −15%	33 cohorts, n = 102,980observational	[174][175]
29	Endurance trainingThe LDL effect of training is small and unreliable – on average −7 mg/dL, with an improvement in only a quarter of the studies. In studies that compared diet and training directly, diet lowered LDL while training alone did little; training raised HDL more than diet did. What training does reliably: it lowers triglycerides (−8 mg/dL), raises HDL (+2.1 mg/dL, from about 120 minutes per week; the duration of each session matters more than the intensity), reduces belly fat, improves insulin action, lowers blood pressure and increases fitness (Lever 28). Whether training lowers ApoB is unproven. Interval training (HIIT) and steady-state training have the same effect on blood pressure, waist circumference and blood lipids; the advantage of HIIT is time.	LDL 0 to −7 mg/dL TG −8 · HDL +2	148 RCTsLDL effect uncertain	[40][41][42][43][177]
30	Isometric training for blood pressureStatic holds – wall sit or handgrip squeezing, typically 4 × 2 minutes with rests in between, so about 8 minutes of holding per session, three times a week. In a network meta-analysis of 270 studies with 16,000 people that compared all forms of training, isometric training showed the largest mean blood pressure reduction: 8/4 mmHg, compared with 4.5/2.5 for endurance or strength training. It can be added to your regular strength training. It has no effect on blood lipids.	Blood pressure −8/−4 mmHg	270 RCTs, n = 15,827very little effort	[191]
31	Strength training and muscle strengthA meta-analysis of 29 studies found an LDL reduction of 6.1 mg/dL. The same authors later recalculated how reliable that figure is and concluded that a new study could just as well find no effect. Strength training is a foundation for muscle mass, belly fat, insulin action and bone – its effect on cholesterol is small. Muscle strength itself is a predictor: in a study of 140,000 people in 17 countries, 5 kg less grip strength meant 17% more cardiovascular death. That is a marker; it does not show that strength training alone prevents heart attacks.	LDL unclear Grip strength: per −5 kg +17% cardiac death	29 RCTscohort n = 139,691	[44][45][176]
32	Steps and everyday movementFor every additional 1,000 steps per day, mortality in cohorts was about 15% lower; the benefit starts at around 2,500 to 4,000 steps and continues past 10,000. For people under 60, the effect on cardiac events is still uncertain in the data. Sitting a lot is linked to up to 2.6-fold higher mortality – and any movement, including light activity like walking or housework, lowers the risk, most of all in the least active. A standing desk does not help here: standing time shows no link to fewer cardiovascular diseases, while prolonged standing is linked to more venous problems.	per 1,000 steps: death −15%	17 cohorts, n = 226,889observational	[172][173][196][197]
33	Break up sitting6 hours of sitting replaced by 4 hours of walking and 2 hours of standing: triglycerides, non-HDL and ApoB measurably better than on the sitting day. Compared with a day that included one hour of intense cycling, the values were also better, though the difference was statistically uncertain. A small study in young healthy people (n = 18) – but a sign that movement spread across the whole day does something a single training session cannot.	TG · non-HDL · ApoB ↓	study n = 18little effort	[54]
34	Walking after meals – 30 minutes at a brisk paceAfter a meal, triglycerides rise for several hours; how much they rise is linked to cardiac risk (remnant cholesterol, see Part 1). In one go or in ten blocks of 3 minutes, equally effective. In a crossover study (each participant goes through both conditions), the triglyceride rise after a test meal on the following day was 16% smaller when the participant had walked briskly for 30 minutes the day before. In a second study, short strength-exercise breaks (3 minutes every 30 minutes over four hours in the evening) lowered the post-meal rise in blood sugar and insulin by 31% and 27% respectively, with no effect on triglycerides. Both measured in young healthy people; two different protocols, and no study of a walk after every meal.	post-meal triglycerides −16%	studies n = 15 / 30	[55][56]
35	Yoga, tai chi, slow breathingYoga lowers blood pressure by about 5/4 mmHg, and in people with high blood pressure, with a breathing and relaxation component three times a week, by up to 11/6 mmHg – the effect depends on the breathing and relaxation, less on the postures. In a 12-month study of 342 people around age 49, tai chi outperformed endurance training on blood pressure by 2.4 mmHg. Slow breathing (under 10 breaths per minute, 10–15 minutes daily) lowers blood pressure by about 5/3 mmHg; you need no device for it – once the manufacturer-funded studies were excluded, the device-guided studies showed no effect. Mindfulness training lowers blood pressure measured at the doctor's office; in 24-hour measurement the effect was statistically uncertain.	Blood pressure −5/−4 mmHg	49 + 17 studiestime needed 3–4×/week	[187][188][189][190]

Group E · Sleep, mind, environment

Risk factors that rarely come up in a cholesterol conversation

Almost everything here is observational data. It shows that a factor goes along with more heart attacks, and usually also a plausible pathway to them (blood pressure, sleep, stress hormones). Whether changing the factor prevents events has been tested less often.

#	Lever	Effect	Evidence	Source
36	Sleep on a regular schedule – at a similar time every dayPeople whose sleep times vary widely have 26% more serious cardiac events – even when they get enough sleep overall (UK Biobank, a British population study, 72,000 people aged 40 to 79). In a second analysis, regularity was a stronger predictor of cardiovascular death than sleep duration. The group that fell asleep between 10 and 11 p.m. had the lowest risk – a comparison between groups; it sets no rule for the individual. In practice: a fixed bedtime and wake-up time, including weekends; the 30 minutes of leeway is my own setting. Sleep duration on its own showed no reliable association with blood lipids (RR 1.01); it remains important for appetite, insulin, and blood pressure.	irregular: events +26%	cohorts n = 72,269observational	[199][200][201][59]
37	Get sleep apnea checkedPauses in breathing during sleep. Severe, untreated sleep apnea is associated with almost three times the risk of cardiovascular death. In the randomized trials in heart patients, the breathing mask (CPAP) produced no reliable reduction in repeat cardiac events overall (HR 1.01). Among those who used the mask for at least four hours per night, the risk was 31% lower – that is an after-the-fact analysis by usage, without random assignment, and therefore weaker evidence. Signs: loud snoring, witnessed pauses in breathing, daytime sleepiness, morning headaches, high blood pressure that responds poorly to medication. A sleep lab settles it.	severe, untreated: cardiac death ×2.7	27 cohorts3 RCTs (CPAP)	[178][179]
38	Stress, depression, lonelinessIn observational studies, chronic work stress is associated with more abdominal fat, higher triglycerides (+7.5 mg/dL), and slightly lower HDL (−1.7 mg/dL); for LDL the association is small (OR 1.14 for elevated LDL, 91,593 employees). Depressive symptoms raise cardiovascular risk by 6–22%; treating the depression improves the depression; whether it also prevents cardiac events is, according to the Cochrane review, very uncertain. Loneliness and social isolation are associated with 29% more coronary heart disease and 32% more strokes – in the same range as physical inactivity. That stress raises LDL directly, or that relaxation training lowers it, is unproven; stress reduction has proven effects on blood pressure and mental health.	loneliness: coronary heart disease +29%	cohort meta-analysesobservational	[110][111][112][113][180][181][182]
39	Traffic noise and fine particulate matterFor every 10 decibels more road traffic noise, the risk of coronary heart disease was 8% higher – rated by the WHO as high-quality evidence; the pathway runs through disturbed sleep and stress hormones. For every 10 µg/m³ of the finest particulate matter (PM2.5 – particles under 2.5 thousandths of a millimeter), mortality from heart disease was 23% higher. What you can influence: bedroom on the quiet side of the building, sound insulation, moving intense sessions to parks or indoors on high-pollution days. Living in green surroundings is associated with 2–3% less cardiovascular death, probably in part through less noise and particulate matter.	per 10 dB: +8% · per 10 µg/m³: +23%	WHO review + meta-analysesobservational	[185][58][195]
40	Shift workShift and night work is associated with 26% more coronary heart disease and 22% more cardiovascular death; the risk rises after about five years and then by 7% for every additional five years. This applies only to people who work shifts. Those who do have the levers that remain: sleep regularity (Lever 36), exercise, and nutrition.	coronary heart disease +26%	21 cohorts, n = 173,010observational	[192]
41	GumsPeriodontitis (chronic gum inflammation) is associated with 20–25% more cardiovascular disease. In one randomized trial, treatment improved vascular function; the effect on blood pressure is inconsistent, and for heart attacks there are no data. Oral hygiene and regular dental check-ups make sense regardless.	cardiovascular disease +20%	30 cohortsobservational	[183][184]
42	SaunaIn Finnish men, 4–7 sauna sessions per week were associated with 63% less sudden cardiac death (HR 0.37) – observational data from Finland, 2,315 men followed over 20 years. Whether the sauna itself is the cause, or whether people who use the sauna often also live healthier in other ways, cannot be determined from this.	sudden cardiac death −63%	cohort n = 2,315transferability open	[57]
43	Cold, ice bathsCold water triggers a short stress response: heart rate and blood pressure rise for a few minutes; there are no studies that have examined blood pressure, blood lipids, or cardiac events over a period of weeks. With undiagnosed high blood pressure, the acute rise in blood pressure is a safety issue. As a cardiovascular measure, unproven.	unproven	24 acute studiesno long-term data	[186]
44	Flu vaccination and hormone therapy – two assessmentsFlu vaccination: In people with existing heart disease, the annual flu vaccination lowers serious cardiac events by a third, and after a recent heart attack by almost half (6 randomized trials). In people with healthy hearts, no effect was measurable. Hormone therapy in menopause: treats symptoms; as protection against heart attack, the US Preventive Services Task Force considers it unsuitable (recommendation against it for preventing chronic disease). The decision belongs with your gynecologist.	vaccination in heart patients: events −34%	6 RCTs, n = 9,001guideline	[193][194]

6 · Supplements, herbs, extracts: what is proven and what is marketed Four have proven effects on LDL, a handful lower blood pressure slightly, the rest are marketed on thin evidence

The 2025 ESC/EAS guideline sees no indication for dietary supplements or vitamins to lower LDL and thereby reduce cardiovascular risk (Class III) [63]. A head-to-head trial fits that picture: six common retail products (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice) produced no measurable LDL reduction over 28 days compared with placebo; 5 mg of rosuvastatin lowered it by 35 % [93]. That tells you something about these products at this dose and duration. Psyllium, beta-glucan, plant sterols and certain probiotics lower LDL measurably over weeks in meta-analyses; whether that translates into fewer heart attacks has been tested directly for none of them. The table is sorted by evidence: first what works, then what is unclear, then what is marketed.

Proven – through different mechanisms

Supplement	Dose	LDL	Assessment	Source
Psyllium huskLever 3	~10 g/day	−13 mg/dL	Also lowers ApoB (GRADE high). Take with plenty of water, and keep a gap between it and any medication.	[23]
Beta-glucanLever 4	≥ 3 g/day	−7 to −10 mg/dL	Authorized EU health claim for lowering cholesterol and for the risk factor for coronary heart disease [210]. Oats are the simplest form.	[24][25]
Plant sterols / stanolsLever 7	1.5–2.4 g → 7–10 % · 2.5–3 g → 10–12.5 %	−9 to −12 %	Authorized EU claim for reducing a disease risk factor, graded by dose; oat beta-glucan has a comparable authorization [210]. Contraindicated in sitosterolemia. A heart attack study is still missing.	[29][30][31]
Probiotics (specific strains)Lever 14	product-dependent, ≥ 8 weeks	−7 to −9 mg/dL	Three meta-analyses agree, partly drawing on the same trials. Strain- and dose-dependent, with no heart attack studies.	[132][133][208]

Effect likely, data quality insufficient

Supplement	Dose	LDL	Assessment	Source
Berberineplant compound from barberry and other plants	~1 g/day	−0.38 mmol/L ≈ −15 mg/dL	Berberine makes the liver produce more LDL receptors, meaning more docking sites that pull LDL out of the blood. The trials partly contradict each other and are methodologically weak. Berberine inhibits a liver enzyme (CYP3A4) that breaks down many medications – interactions are possible. Its legal status in the EU is unresolved.	[67][68]
Amla (Indian gooseberry)	500–1,500 mg/day	−15 mg/dL	Nine small trials, almost all from India, mostly in people with a lipid disorder or diabetes. The results scatter so widely that the effect in an individual case can also be zero.	[157]
Fenugreekseeds of a culinary herb, as powder or capsule	–	−11 mg/dL	Studied almost exclusively in people with diabetes; also lowers blood sugar there. Use caution with blood sugar medication, and avoid during pregnancy.	[158]
Spirulinaa blue-green alga, as powder or tablet	–	unclear	Large LDL effects from small trials, mostly from Asia and in people with elevated values. The main problem is product quality: contamination with algal toxins and heavy metals when the source is uncontrolled.	[160]
Krill oiloil from small crustaceans, provides omega-3 fatty acids	–	−15 mg/dL (wide interval)	Seven small trials; no proven advantage over fish oil, and more expensive. Keep shellfish allergy in mind.	[169]

Blood pressure: small, proven effects

Supplement	Dose	Blood pressure	Assessment	Source
Aged garlic extractgarlic fermented for months; as a capsule	–	−8/−5 mmHg in hypertension	Little effect at normal blood pressure. For LDL, the garlic data are contradictory (see below). Increases bleeding tendency with anticoagulants.	[148]
L-argininean amino acid the body uses to produce nitric oxide, which widens blood vessels	up to 9 g/day	−6/−3 mmHg	22 trials, including in healthy people. Contraindicated after a heart attack: a trial using 9 g daily was stopped after six deaths in the arginine group. L-citrulline, its precursor, shows no blood pressure effect.	[152][153][154]
Taurinean amino acid derivative, also found in energy drinks	1–6 g/day	−4/−1 mmHg	Very small trials, many in people with heart disease; well tolerated; unclear at normal blood pressure.	[162]
Olive leaf extractextract from the leaves of the olive tree	–	−4/−2 mmHg	Small trials; practically no effect on LDL.	[156]
Quercetina plant pigment from onions, apples and berries	≥ 500 mg/day	−3/−3 mmHg	Blood lipids and blood sugar stay unchanged.	[161]
Melatoninthe sleep hormone, as a tablet or spray	–	−3/−3 mmHg	Small trials, mostly in people with metabolic disease; LDL unchanged. Whether a product counts as a medicine or a supplement depends on dose and purpose; interactions with blood thinners and blood pressure medication.	[168]

Works – with reservations

Supplement	Dose	LDL	Assessment	Source
Red yeast ricerice fermented with a mold · works – because it is a statin	Study doses prohibited in the EU since 2022	−39 mg/dL	The active ingredient monacolin K is chemically identical to the statin lovastatin. The Chinese preparation Xuezhikang nearly halved cardiac events in a trial of 5,000 heart attack patients – with exactly the advantages and drawbacks of a statin. The European food safety authority EFSA has documented serious side effects at doses as low as 3 mg/day and could set no safe intake level. EU: below 3 mg/day with a warning label (Regulation 2022/860), health claim removed (Regulation 2024/2041); the committee of member states voted in favor of a full ban on May 13, 2026 [209]; as of my check on October 8, 2026, the regulation had yet to appear in the Official Journal, so the 3 mg limit applies until then. A statin-level reduction belongs in your doctor's hands.	[69][70][71][72][73][170]
Omega-3 (EPA/DHA)the two omega-3 fatty acids from fish, as a capsule · lowers triglycerides, raises LDL	1–2 g/day	+8.9 mg/dL (DHA)	Lowers triglycerides (−0.20 mmol/L) and raises LDL slightly. On heart attacks the picture is split: high-dose pure EPA (4 g, a prescription drug) cut events by 25% in high-risk patients with elevated triglycerides; an EPA/DHA mix at the same dose did not. Regular fish oil (1 g/day) gave the general population (26,000 people, five years) no measurable protection. On top of that, the risk of atrial fibrillation rises with the dose: +12% up to 1 g, +49% above that. Useful for elevated triglycerides when your doctor judges it appropriate; unsuitable for lowering LDL.	[74][75][141][142][143][144]
Niacinvitamin B3 in high doses · improves the numbers without preventing heart attacks	–	↓	Lowers LDL, lowers triglycerides, raises HDL – and in 23 RCTs (n = 39,195) produced no confirmed reduction in heart attacks, strokes or deaths. Discontinuation due to side effects RR 2.17. More diabetes, infections, bleeding.	[76][77][78]

Marketed, unproven

Supplement	LDL / blood pressure	Assessment	Source
Vitamin E · Vitamin C · Beta-caroteneantioxidants – substances meant to neutralize aggressive oxygen compounds	Events: no confirmed effect	Zero protection against heart attacks (50 trials, 294,000 people). High-dose vitamin E (400 IU and up) and beta-carotene raise mortality by 3–5% in large analyses. Vitamin C lowers blood pressure by 4 mmHg in small short-term trials, with no event data.	[145][146][206]
Multivitaminscombination products with many vitamins and minerals	Events: no confirmed effect	Eleven years of a daily multivitamin in 14,600 men aged 50 and over: no difference in heart attack, stroke or cardiovascular death.	[147]
Astaxanthinred pigment from algae that colors salmon and crustaceans	LDL: no confirmed effect	Three industry-independent meta-analyses: no LDL effect. Against placebo, LDL fell even less under astaxanthin. EFSA rejected the requested health claims on antioxidation and cholesterol; a heart attack trial does not exist. A signal only for triglycerides/HDL. Safe up to 8 mg/day.	[79][80][81][82][83][84]
Magnesium · Vitamin D · Vitamin K2 · Coenzyme Q10 · Policosanola mineral, two vitamins, a cell building block, a wax substance from sugar cane	LDL 0 to −3 mg/dL	Magnesium: no effect on LDL (meta-analysis, p = 0.90). Vitamin D: LDL +3.2 mg/dL across 12 trials (still worthwhile for other reasons). K2: a single trial with 46 participants, no meta-analysis – a hypothesis. Coenzyme Q10: in a meta-analysis of 50 trials LDL −3 mg/dL and triglycerides −9 mg/dL – statistically visible, practically small; event data are missing. Policosanol: a network meta-analysis across 131 trials, in its own words “no effect on the lipid profile”.	[85][86][87][207]
Nattokinaseenzyme from natto, fermented soybeans	Blood vessels: no confirmed effect	The only multi-year randomized trial I found (265 people, three years) showed no effect on vessel walls, blood pressure or blood values; at the low dose, LDL tended to rise. It has anticoagulant activity – bleeding risk with blood thinners.	[149]
Resveratrolplant compound from grapes and red wine	LDL: no effect · HDL −4	Lowers neither LDL nor blood pressure; in an analysis of ten trials, HDL fell by 4 mg/dL.	[150]
NMN / NAD precursorsprecursors of the cell molecule NAD, marketed as anti-aging agents	LDL: no confirmed effect	Eight trials pooled: no effect on blood lipids or blood sugar.	[151]
Hawthornmedicinal plant, traditionally used for heart failure	Events: no confirmed effect	Relieves symptoms of heart failure. In the large endpoint trial (2,700 heart failure patients, two years) no protection against cardiac events; for blood pressure and blood lipids, no reliable data.	[155]
Garlic · Curcumin · Green tea extract · Artichoke · Bergamot · Ginger · Cinnamonkitchen plants and their extracts (curcumin is the yellow pigment in turmeric, bergamot a citrus fruit) · small or uncertain	0 to −9 mg/dL	Garlic: two meta-analyses, opposite results (for blood pressure see above). Curcumin: −4.9 mg/dL at GRADE “low”, liver signals. Green tea extract: −4.5 mg/dL, liver damage documented from 800 mg EGCG upward. Artichoke: Cochrane “not convincing”. Bergamot: numerically large (−47 mg/dL), very thin data base and partly unblinded. Ginger: as a capsule, no LDL effect. Cinnamon: −0.8 mg/dL, statistically visible, practically meaningless.	[87][88][89][90][91][92][159][139]
Apple cider vinegar · Chromium · Selenium · Zinc · Collagen · Glycinea home remedy, three trace elements, a protein and an amino acid	LDL: no confirmed effect	Apple cider vinegar: total cholesterol −6 mg/dL, LDL unchanged. Chromium: no effect in eight meta-analyses. Selenium: no lipid effect; 200 µg/day raised diabetes risk by 55% in one trial. Zinc: studied only in diabetics. Collagen: effects barely reach statistical significance across highly contradictory trials; for glycine alone there are no data.	[138][163][164][167]
Essential oils · Aromatherapy · CBDfragrance oils, their use, and cannabidiol – a hemp compound without intoxicating effect	Long-term blood pressure: no confirmed effect	Aromatherapy relaxes in the short term; for high blood pressure there is one randomized trial, and the review of it finds no convincing evidence. For blood lipids there are no studies. CBD lowered blood pressure by about 5 mmHg in two small trials; far too early for a recommendation, and it interacts with statins and blood thinners via liver enzymes.	[165][166]
Danshen (Chinese sage)root from Chinese medicine	unproven	A single proper randomized trial; no proven benefit.	[171]

Andreas explainsIn short

I take supplements, and I adjusted them deliberately after my screening. Even so, read the table as it stands: four things have a proven effect on LDL, a handful lower blood pressure a little, and the rest is marketed.

What you eat weighs more than what you add to it. My return to the normal range came from both – and diet was the larger part.

7 · Where the medications stand A benchmark so you can put the numbers above into context – your doctor decides about medication

Drug	LDL	Fewer heart attacks proven?	Source
Statin, moderate / high doseTablet, slows the liver's cholesterol production	≈ −30 % / −50 %	CTT (the pooled analysis of all large statin trials): −22 % events per 39 mg/dL, 26 RCTs	[11][13]
Statin + ezetimibeEzetimibe: tablet, blocks cholesterol absorption in the gut; an additional −15 to −20 % on the value remaining under a statin; in the IMPROVE-IT trial it was 23 %	combined ≈ −65 %	Outcome trial IMPROVE-IT: events reduced	[96][13][213]
PCSK9 inhibitorInjection every two to four weeks; the liver takes up more LDL from the blood	≈ −60 % alone · with a high-dose statin ≈ −75 % · with statin and ezetimibe ≈ −85 %	Two outcome trials (FOURIER, ODYSSEY OUTCOMES): events reduced	[97][98][13]
Bempedoic acidTablet, works similarly to a statin, but only in the liver	−23 % alone · −38 % with ezetimibe	Outcome trial CLEAR Outcomes: events HR 0.87; cardiovascular mortality unchanged	[99][63]
InclisiranInjection: at the start, after three months, then every six months	≈ −50 %	LDL reduction proven (ORION-10/11); the outcome trial ORION-4 is ongoing – when I checked on October 8, 2026, no published results were available	[100]

A statin lowers LDL by 30 to 50 %, a change in diet by 10 to 15 %. Per milligram lowered, the benefit is the same [12]. The levers add up: if you take a statin and live the portfolio principle, you lower it further.

8 · How to put it into practice starting tomorrow Five habits, twelve weeks – actions that fit into your everyday life

The rule of thumb, no calculation needed:

Oats in the morning3 g beta-glucan ≈ 70–80 g rolled oats

A handful of nuts30–60 g, any kind

One serving of legumes~130 g lentils, beans, chickpeas

Olive oil as your default fatButter, processed meat, cream → olive oil, canola oil, fish

Paper filter for your coffeeswitch once, done

This is a model calculation, and only that: if you add up the individual effects of these five habits from the studies and subtract 25 % because the mechanisms overlap (the deduction is my own assumption), you end up at roughly 28 mg/dL less LDL. Using the statin conversion above, that would correspond to roughly 16 % fewer cardiovascular events. How much that means for you in absolute terms depends on your baseline risk, and whether the five habits together deliver this reduction has never been tested as a package.

Measure properly. Lipid profile + ApoB, Lp(a) once in your life, plus TSH, HbA1c and home blood pressure over 7 days. The routine test works without fasting. Until you have these numbers, you are guessing.
Set the five habits – one per week. That way each one sticks. Quitting smoking and blood pressure, where relevant, come before any cholesterol lever.
Choose two standard meals. Find two dishes you enjoy that carry several levers (overnight oats with nuts, lentil salad with olive oil) and make them your standard. A portfolio you like is a portfolio you eat.
Supplement selectively. Psyllium husk (10 g) and plant sterols (2 g) are the two supplements with a measurable contribution to the total reduction. Omega-3 only if your triglycerides are elevated.
Measure again – after twelve weeks. Same test, same lab. If you miss the mark: check the causes in Section 4. Your LDL has a strong genetic component – you have done what diet and lifestyle can do, and that benefit stays with you. The rest you discuss with your doctor – with your numbers in hand.

Andreas explainsIn short

That was a lot. Take it the way I did back then: one step, then the next. For me it took years, with many detours – you now have the shortcut in your hands.

My line from coaching applies here too: anything that fails to become an action in your everyday life has no value. Pick the one habit out of the five that you will start tomorrow. And if you want support – with the screening or with putting it into practice – get in touch with me.

New lessons & recipes every two weeks

The nutrition pillar keeps growing — grounded lessons, every number sourced, and recipes that put the knowledge on a plate. Sign up and you'll get them first.

Join the newsletter

Appendix

Glossary and sources

Every technical term explained, every number with a source.

Glossary The technical terms from this article, briefly explained

ApoB (apolipoprotein B) – a protein on the surface of every particle that can carry cholesterol into the artery wall. One ApoB per particle; the measured ApoB concentration is therefore a measure of how many of these particles there are.

Atherosclerosis / plaque – deposits in the artery wall made of cholesterol, cells and calcium. When a plaque ruptures, a clot forms: heart attack or stroke.

Beta-glucan – the soluble fiber in oats and barley. Binds bile acids in the gut.

CAC score (coronary artery calcium score) – the amount of calcium in the coronary arteries, measured by computed tomography. A score of zero means no calcified deposits were detectable.

Cafestol – a compound in coffee oil that raises LDL. A paper filter holds it back.

Coronary heart disease (CHD) – narrowing of the coronary arteries by plaques. Consequences: chest tightness on exertion, heart attack. Often counted as an endpoint in studies.

CPAP – a breathing mask with mild positive pressure, the treatment for sleep apnea.

Crossover study – a study in which every participant goes through both conditions, for example one day with a walk and one day without. Each person serves as their own control group.

DASH (Dietary Approaches to Stop Hypertension) – a dietary pattern against high blood pressure that has been tested in studies: plenty of vegetables, fruit, legumes, whole grains, low-fat dairy, little salt.

EFSA – the European Food Safety Authority. Among other things, it checks whether advertising claims about foods are backed by evidence.

Endpoint study / hard endpoints – a study that counts what actually happens – heart attack, stroke, death. Its counterpart is a study that only measures how a blood value changes. Only endpoint studies prove that a measure prevents events.

ESC / EAS – the European Society of Cardiology and the European Atherosclerosis Society, the European professional societies for heart medicine and arterial disease. The guidelines of these societies set the target values.

Event (cardiovascular event) – the umbrella term in studies for heart attack, stroke, cardiovascular death and usually also stent or bypass.

Familial hypercholesterolemia (FH) – an inherited disorder in which the liver removes too little LDL from the blood. LDL is high from birth; about 1 in 313 people is affected.

Fiber – plant components the small intestine does not digest. Soluble fiber (oats, psyllium, legumes) binds bile acids and lowers LDL; insoluble fiber (whole grains, vegetables) acts mainly on digestion.

GRADE – a rating system that sorts the reliability of a body of evidence into four levels: high, moderate, low, very low.

HbA1c (glycated hemoglobin) – long-term blood sugar; shows the average of roughly the last three months.

HDL (high-density lipoprotein) – the transport particle that carries excess cholesterol from the body back to the liver. A low value points to metabolic problems; raising the value on its own brings no benefit.

Health claim (EU) – a health-related advertising statement that the EU permits only when the food safety authority EFSA considers the effect proven.

HIIT – high-intensity interval training, alternating short intense efforts with rest periods.

Insulin sensitivity – how well your cells respond to insulin and take up sugar from the blood. When it drops, blood sugar, triglycerides and belly fat go up.

Isometric training – muscle contraction without movement, for example a wall sit or handgrip squeeze.

Ketogenic diet – a diet with very few carbohydrates and a great deal of fat. Raises LDL, sharply in people of normal weight.

LDL (low-density lipoprotein) – the transport particle that carries cholesterol from the liver into the body; these are the particles that deposit in the artery wall. “LDL level” = the amount of cholesterol in these particles.

Lipid panel – the standard blood test: total cholesterol, LDL, HDL, triglycerides.

Lipoprotein – a transport particle made of fat and protein in which cholesterol and triglycerides travel through the blood. LDL, HDL, VLDL and Lp(a) are lipoproteins.

Lp(a), lipoprotein(a) – an LDL particle with an extra protein attachment; it deposits especially easily. Over 90 % inherited, measure it once in your life.

Mendelian randomization – a study design that uses randomly inherited gene variants as a natural experiment. People who carry a variant that lowers LDL for life show what lowering LDL does in itself – independent of lifestyle.

MET / VO₂max – measures of endurance capacity. 1 MET is the energy expenditure at rest, a fixed reference value; the capacity a person reaches in METs rises with training. VO₂max is the largest amount of oxygen the body can process per minute.

Meta-analysis – statistically combines the results of many studies on one question into a single number. A network meta-analysis compares several measures at the same time.

mmHg – millimeters of mercury, the unit of blood pressure. The first number (systolic, the “upper value”) is the pressure during the heartbeat, the second (diastolic, the “lower value”) the pressure between beats. From 140/90 upward, blood pressure counts as elevated.

Monacolin K – the active compound in red yeast rice, chemically identical to the statin lovastatin.

Non-HDL cholesterol – total cholesterol minus HDL, in other words the cholesterol in all the particles that can deposit in the artery wall.

Observational study / cohort – a study that follows people over years without intervening. It shows associations; causation stays open, because people with one habit differ in other ways as well.

Omega-3 fatty acids (EPA/DHA) – two fatty acids from oily fish (salmon, mackerel, herring). They lower triglycerides; as a capsule, DHA-containing products raise LDL slightly.

Phytosterols / plant sterols – plant compounds that resemble cholesterol and take its absorption sites away in the gut.

Placebo – a dummy preparation with no active ingredient. The control group receives it so that the effect of expectation can be separated from the effect of the substance.

PM2.5 – fine particulate matter with particles under 2.5 thousandths of a millimeter; so small that it passes from the lungs into the blood.

Probiotics – live bacteria taken deliberately – as a supplement or in foods. The effect depends on the specific bacterial strain.

RCT (randomized controlled trial) – a study in which participants are assigned by lot to the intervention and the control group.

Remnant cholesterol – the cholesterol in the residual particles left over after triglyceride-rich particles have been broken down. It deposits in the artery wall as well.

RR, OR, HR (relative risk, odds ratio, hazard ratio) – comparison figures between two groups. 1.0 means no difference. For relative risk, 0.8 is exactly 20 % less; odds ratio and hazard ratio come close to that for rare events and diverge from it for common events.

Saturated fat – fat that is solid at room temperature: butter, processed meat, cheese, cream, coconut and palm fat. It slows the uptake of LDL into the liver and so raises LDL in the blood. Unsaturated fat (olive oil, canola oil, nuts, fish) is liquid and lowers it.

SCORE2 – the risk calculator of the European guideline; it estimates the 10-year risk of heart attack and stroke from age, sex, blood pressure, smoking and cholesterol.

Sitosterolemia – a very rare hereditary disease in which the gut absorbs plant sterols it would otherwise reject. Phytosterol products are then off limits.

Sleep apnea – pauses in breathing during sleep caused by a closed throat; leads to oxygen shortage, a rise in blood pressure and unrefreshing sleep.

Statin – the usual cholesterol medications (e.g. atorvastatin, rosuvastatin). They slow cholesterol production in the liver; the liver then pulls more LDL out of the blood.

Stent / bypass – two procedures for narrowed coronary arteries: a stent is a small tube that holds the vessel open from the inside; a bypass is a detour made from one of the body's own vessels. Anyone who has had either of them counts as “very high risk”.

TMAO (trimethylamine N-oxide) – a compound that gut bacteria form from choline and carnitine (red meat, eggs). Linked to heart disease; whether it causes it remains unresolved.

Triglycerides – the storage fat in the blood. They respond quickly to sugar, alcohol, weight and exercise.

TSH (thyroid-stimulating hormone) – the thyroid value. A high TSH is the first sign of an underactive thyroid, a common cause of high LDL; the diagnosis needs further values.

Visceral fat / belly fat – fat around the internal organs. It drives inflammation, insulin resistance and triglycerides.

VLDL (very-low-density lipoprotein) – the transport particle for triglycerides, which turns into LDL along the way.

Sources Every entry checked against the primary source (Crossref + PubMed abstract, Oct 8, 2026). Evidence type and population are given with each one.

Shi Q et al. (2022). Intracellular cholesterol synthesis and transport. Front Cell Dev Biol 10:819281. 10.3389/fcell.2022.819281 Review · order of magnitude
Luo J, Yang H, Song BL (2020). Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 21(4):225–245. 10.1038/s41580-019-0190-7 Review
Ference BA et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J 38(32):2459–2472. 10.1093/eurheartj/ehx144 EAS consensus · genetics + cohorts + RCTs
Sniderman AD et al. (2019). Apolipoprotein B particles and cardiovascular disease. JAMA Cardiol 4(12):1287–1295. 10.1001/jamacardio.2019.3780 Review
Marston NA et al. (2022). Association of apolipoprotein B–containing lipoproteins and risk of myocardial infarction. JAMA Cardiol 7(3):250–256. 10.1001/jamacardio.2021.5083 Cohort n = 389,529 + 2 RCT cohorts · general population
Voight BF et al. (2012). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841):572–580. 10.1016/S0140-6736(12)60312-2 Mendelian randomization
Barter PJ et al. (2007) ILLUMINATE, NEJM 357(21):2109–2122, 10.1056/NEJMoa0706628 · Schwartz GG et al. (2012) dal-OUTCOMES, NEJM 367(22):2089–2099, 10.1056/NEJMoa1206797 · Lincoff AM et al. (2017) ACCELERATE, NEJM 376(20):1933–1942, 10.1056/NEJMoa1609581 · HPS3/TIMI55-REVEAL (2017), NEJM 377(13):1217–1227, 10.1056/NEJMoa1706444 RCTs · high-risk patients
Das Pradhan A et al. (2022). Triglyceride lowering with pemafibrate to reduce cardiovascular risk (PROMINENT). NEJM 387(21):1923–1934. 10.1056/NEJMoa2210645 RCT n = 10,497 · type 2 diabetes
Ference BA et al. (2019). Association of triglyceride-lowering LPL variants and LDL-C–lowering LDLR variants with risk of coronary heart disease. JAMA 321(4):364–373. 10.1001/jama.2018.20045 Mendelian randomization n = 654,783
Kronenberg F et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: EAS consensus statement. Eur Heart J 43(39):3925–3946. 10.1093/eurheartj/ehac361 EAS consensus · "one in five" is converted from ≈ 1.4 billion worldwide
Cholesterol Treatment Trialists' Collaboration (2010). Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet 376(9753):1670–1681. 10.1016/S0140-6736(10)61350-5 · CTT (2012), Lancet 380(9841):581–590, 10.1016/S0140-6736(12)60367-5 Individual-participant-data meta-analysis, 26 RCTs, n ≈ 170,000
Silverman MG et al. (2016). Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. JAMA 316(12):1289–1297. 10.1001/jama.2016.13985 Meta-analysis, 49 RCTs, n = 312,175
Mach F et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 41(1):111–188. 10.1093/eurheartj/ehz455 Guideline · target values, secondary causes, drug potencies
Willeit P et al. (2018). Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events. Lancet 392(10155):1311–1320. 10.1016/S0140-6736(18)31652-0 IPD meta-analysis, 7 statin RCTs, n = 29,069
Varbo A et al. (2013). Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61(4):427–436. 10.1016/j.jacc.2012.08.1026 Mendelian randomization n = 73,513
Vincent MJ et al. (2019). Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. Am J Clin Nutr 109(1):7–16. 10.1093/ajcn/nqy273 55 RCTs, n = 2,652 · funded by the Egg Nutrition Center
Rong Y et al. (2013). Egg consumption and risk of coronary heart disease and stroke. BMJ 346:e8539. 10.1136/bmj.e8539 Cohort meta-analysis · observational, no causality
Nordestgaard BG et al. (2016). Fasting is not routinely required for determination of a lipid profile. Eur Heart J 37(25):1944–1958. 10.1093/eurheartj/ehw152 EAS/EFLM consensus
Jenkins DJA et al. (2011). Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice. JAMA 306(8):831–839. 10.1001/jama.2011.1202 RCT, 6 months, 351 randomized / 345 analyzed · hyperlipidemia, free-living
Chiavaroli L et al. (2018). Portfolio dietary pattern and cardiovascular disease. Prog Cardiovasc Dis 61(1):43–53. 10.1016/j.pcad.2018.05.004 Meta-analysis, 7 comparisons, n = 439 · GRADE high
Mensink RP, WHO (2016). Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. Geneva: WHO. WHO IRIS 10665/246104 Meta-regression, 84 feeding studies · mostly healthy adults · 5 E% extrapolation = model calculation
Hooper L et al. (2020). Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 8:CD011737. 10.1002/14651858.CD011737.pub3 15 RCTs, n = 56,675 · events RR 0.83 (12 studies, n = 53,758), GRADE moderate · all-cause mortality RR 0.96 (n.s.)
Jovanovski E et al. (2018). Effect of psyllium fiber on LDL cholesterol and alternative lipid targets. Am J Clin Nutr 108(5):922–932. 10.1093/ajcn/nqy115 28 RCTs, n = 1,924, median 10.2 g/day
Whitehead A et al. (2014). Cholesterol-lowering effects of oat β-glucan. Am J Clin Nutr 100(6):1413–1421. 10.3945/ajcn.114.086108 28 RCTs, ≥ 3 g/day: LDL −0.25 mmol/L
Ho HVT et al. (2016). The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB. Br J Nutr 116(8):1369–1382. 10.1017/S000711451600341X 58 RCTs, n = 3,974, median dose 3.5 g/day: LDL −0.19 mmol/L
Del Gobbo LC et al. (2015). Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure. Am J Clin Nutr 102(6):1347–1356. 10.3945/ajcn.115.110965 61 studies, n = 2,582 · adults without existing heart disease
Dattilo AM, Kris-Etherton PM (1992). Effects of weight reduction on blood lipids and lipoproteins. Am J Clin Nutr 56(2):320–328. 10.1093/ajcn/56.2.320 70 studies · overweight participants · per-kg values for LDL/TG from the full text
Hasan B et al. (2020). Weight loss and serum lipids in overweight and obese adults. J Clin Endocrinol Metab 105(12):3695–3703. 10.1210/clinem/dgaa673 73 RCTs, n = 32,496 · BMI ≈ 36 · lifestyle, 12 months: LDL −1.28 mg/dL per kg
Demonty I et al. (2009). Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 139(2):271–284. 10.3945/jn.108.095125 84 RCTs
Ras RT et al. (2014). LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges. Br J Nutr 112(2):214–219. 10.1017/S0007114514000750 124 studies · effect rises up to ≈ 3 g/day to an average of 12 %
Verordnung (EU) Nr. 686/2014 der Kommission [Commission Regulation (EU) No 686/2014: graded disease-risk-reduction claim for plant sterols/stanols]. EUR-Lex 32014R0686 EU regulation
Ha V et al. (2014). Effect of dietary pulse intake on established therapeutic lipid targets. CMAJ 186(8):E252–E262. 10.1503/cmaj.131727 26 RCTs, n = 1,037, median 130 g/day · ApoB n.s.
Blanco Mejia S et al. (2019). A meta-analysis of 46 studies identified by the FDA demonstrates that soy protein decreases circulating LDL. J Nutr 149(6):968–981. 10.1093/jn/nxz020 46 studies (41 with LDL data), median 25 g/day
Urgert R et al. (1997). Separate effects of the coffee diterpenes cafestol and kahweol on serum lipids. Am J Clin Nutr 65(2):519–524. 10.1093/ajcn/65.2.519 Crossover RCT, n = 10 healthy men · purified dose, no placebo arm
Gross G et al. (1997). Analysis of the content of the diterpenes cafestol and kahweol in coffee brews. Food Chem Toxicol 35(6):547–554. 10.1016/S0278-6915(96)00123-8 Analysis by brewing method
Te Morenga LA et al. (2014). Dietary sugars and cardiometabolic risk. Am J Clin Nutr 100(1):65–79. 10.3945/ajcn.113.081521 39 RCTs (37 with lipid data)
David Wang D et al. (2014). Effect of fructose on postprandial triglycerides. Atherosclerosis 232(1):125–133. 10.1016/j.atherosclerosis.2013.10.019 Meta-analysis · isocaloric vs. hypercaloric
Rimm EB et al. (1999). Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 319(7224):1523–1528. 10.1136/bmj.319.7224.1523 42 studies · healthy adults
Holmes MV et al. (2014). Association between alcohol and cardiovascular disease: Mendelian randomisation analysis. BMJ 349:g4164. 10.1136/bmj.g4164 Mendelian randomization, n = 261,991
Smart NA et al. (2025). The effect of exercise training on blood lipids. Sports Med 55(1):67–78. 10.1007/s40279-024-02115-z 148 RCTs, n = 8,673 · improvement in only a quarter of the studies
Kelley GA et al. (2012). Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults. Clin Nutr 31(2):156–167. 10.1016/j.clnu.2011.11.011 6 RCTs, n = 788 · diet lowers LDL, exercise alone does not
Khalafi M et al. (2023). Exercise training, dietary intervention, or combined interventions and their effects on lipid profiles in adults with overweight and obesity. Nutr Metab Cardiovasc Dis 33(9):1662–1683. 10.1016/j.numecd.2023.05.024 80 RCTs, n = 4,804 · overweight/obesity · exercise raises HDL more than diet
Kodama S et al. (2007). Effect of aerobic exercise training on serum levels of HDL cholesterol. Arch Intern Med 167(10):999–1008. 10.1001/archinte.167.10.999 25 RCTs · minimum dose 120 min/week
Kelley GA, Kelley KS (2009). Impact of progressive resistance training on lipids and lipoproteins in adults. Prev Med 48(1):9–19. 10.1016/j.ypmed.2008.10.010 29 RCTs, n = 1,329
Kelley GA, Kelley KS (2009). Another look at a meta-analysis using prediction intervals. Prev Med 49(6):473–475. 10.1016/j.ypmed.2009.09.018 Reanalysis · all prediction intervals include 0
Ettehad D et al. (2016). Blood pressure lowering for prevention of cardiovascular disease and death. Lancet 387(10022):957–967. 10.1016/S0140-6736(15)01225-8 123 RCTs, n = 613,815 · per −10 mmHg: MACE RR 0.80, all-cause mortality RR 0.87
Siervo M et al. (2015). Effects of the DASH diet on cardiovascular risk factors. Br J Nutr 113(1):1–15. 10.1017/S0007114514003341 20 RCTs, n = 1,917 · also LDL −0.10 mmol/L
He FJ, Li J, MacGregor GA (2013). Effect of longer term modest salt reduction on blood pressure. BMJ 346:f1325. 10.1136/bmj.f1325 34 RCTs, n = 3,230 · −4.4 g salt/day
Filippini T et al. (2017). The effect of potassium supplementation on blood pressure in hypertensive subjects. Int J Cardiol 230:127–135. 10.1016/j.ijcard.2016.12.048 Meta-analysis of RCTs · hypertensive participants only · SBP −4.5 mmHg
Siervo M et al. (2013). Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults. J Nutr 143(6):818–826. 10.3945/jn.112.170233 16 crossover studies, n = 254 · 2 h to 15 days · DBP n.s.
Ried K, Fakler P, Stocks NP (2017). Effect of cocoa on blood pressure. Cochrane Database Syst Rev 4:CD008893. 10.1002/14651858.CD008893.pub3 35 RCTs, n = 1,804 · moderate quality
Maeda K et al. (2003). The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles. Prev Med 37(4):283–290. 10.1016/s0091-7435(03)00110-5 27 studies
Gepner AD et al. (2011). Effects of smoking and smoking cessation on lipids and lipoproteins. Am Heart J 161(1):145–151. 10.1016/j.ahj.2010.09.023 RCT, 1,504 randomized, 923 followed up after 1 year
Duvivier BMFM et al. (2013). Minimal intensity physical activity (standing and walking) of longer duration improves insulin action and plasma lipids more than shorter periods of moderate to vigorous exercise. PLoS One 8(2):e55542. 10.1371/journal.pone.0055542 Crossover n = 18 · young healthy adults (age 21) · 4 days per regimen
Miyashita M et al. (2008). Accumulating short bouts of brisk walking reduces postprandial plasma triacylglycerol. Am J Clin Nutr 88(5):1225–1231. 10.3945/ajcn.2008.26493 Crossover n = 15 · young healthy men
Gale JT et al. (2023). Breaking up evening sitting with resistance activity improves postprandial glycemic response. Med Sci Sports Exerc 55(8):1471–1480. 10.1249/MSS.0000000000003166 Crossover n = 30 · young adults · TG unchanged
Laukkanen T et al. (2015). Association between sauna bathing and fatal cardiovascular and all-cause mortality events. JAMA Intern Med 175(4):542–548. 10.1001/jamainternmed.2014.8187 Cohort n = 2,315 Finnish men, 20.7 years · observational
Alexeeff SE et al. (2021). Long-term PM2.5 exposure and risks of ischemic heart disease and stroke events. J Am Heart Assoc 10(1):e016890. 10.1161/JAHA.120.016890 Meta-analysis, 42 studies · per 10 µg/m³: IHD mortality +23 %
Kruisbrink M et al. (2017). Association of sleep duration and quality with blood lipids. BMJ Open 7(12):e018585. 10.1136/bmjopen-2017-018585 6 pooled studies, n = 30,033 · short sleep RR 1.01
Li X et al. (2017). The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 87(1):1–9. 10.1111/cen.13338 12 RCTs, n = 940 · LDL −0.22 mmol/L
Kotwal A et al. (2020). Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis. J Clin Endocrinol Metab 105(12). 10.1210/clinem/dgaa672 Meta-analysis · overt hypothyroidism: LDL −41 mg/dL
Beheshti SO et al. (2020). Worldwide prevalence of familial hypercholesterolemia. J Am Coll Cardiol 75(20):2553–2566. 10.1016/j.jacc.2020.03.057 Meta-analysis, 10.9 million people · 0.32 % ≈ 1:313
Mach F et al. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359–4378. 10.1093/eurheartj/ehaf190 Guideline · target values unchanged · Lp(a) > 50 mg/dL risk modifier · supplements class III
Matthews KA et al. (2009). Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54(25):2366–2373. 10.1016/j.jacc.2009.10.009 SWAN cohort · observational
Wu B et al. (2023). Trajectories of blood lipids profile in midlife women: does menopause matter? J Am Heart Assoc 12(22):e030388. 10.1161/JAHA.123.030388 SWAN cohort n = 2,582
Dibben G et al. (2021). Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 11:CD001800. 10.1002/14651858.CD001800.pub4 85 RCTs, n = 23,430 · secondary prevention · MI RR 0.72, GRADE high
Ju J et al. (2018). Efficacy and safety of berberine for dyslipidaemias. Phytomedicine 50:25–34. 10.1016/j.phymed.2018.09.212 16 RCTs, n = 2,147 · high heterogeneity, high risk of bias
Kong W et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism. Nat Med 10(12):1344–1351. 10.1038/nm1135 Mechanism
Gerards MC et al. (2015). Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain. Atherosclerosis 240(2):415–423. 10.1016/j.atherosclerosis.2015.04.004 20 RCTs · LDL −1.02 mmol/L
EFSA (2018). Scientific opinion on the safety of monacolins in red yeast rice. EFSA Journal 16(8):5368. 10.2903/j.efsa.2018.5368 Regulatory assessment
EFSA (2025). Scientific opinion on additional scientific data related to the safety of monacolins. EFSA Journal 23(2):e9276. 10.2903/j.efsa.2025.9276 Regulatory assessment · no safe intake level
Verordnung (EU) 2022/860 der Kommission [Commission Regulation (EU) 2022/860: monacolins from red yeast rice, ≥ 3 mg per daily portion prohibited]. EUR-Lex 32022R0860 EU regulation, in force since June 22, 2022
Verordnung (EU) 2024/2041 der Kommission [Commission Regulation (EU) 2024/2041: monacolin K health claim withdrawn]. EUR-Lex 32024R2041 EU regulation · full ban: SCoPAFF vote May 13, 2026, publication in the Official Journal pending (as of Oct 8, 2026)
Bernstein AM et al. (2012). A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr 142(1):99–104. 10.3945/jn.111.148973 11 RCTs, n = 485 · without CHD · median 1.68 g/day
Chen G et al. (2020). Effects of EPA and DHA versus α-linolenic acid supplementation on cardiometabolic risk factors. Food Funct 11(3):1919–1932. 10.1039/c9fo03052b 14 RCTs · no placebo comparison
Schandelmaier S et al. (2017). Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev 6:CD009744. 10.1002/14651858.CD009744.pub2 23 RCTs, n = 39,195
AIM-HIGH Investigators (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEJM 365(24):2255–2267. 10.1056/NEJMoa1107579 RCT
HPS2-THRIVE Collaborative Group (2014). Effects of extended-release niacin with laropiprant in high-risk patients. NEJM 371(3):203–212. 10.1056/NEJMoa1300955 RCT
Ursoniu S et al. (2015). Lipid profile and glucose changes after supplementation with astaxanthin. Arch Med Sci 11(2):253–266. 10.5114/aoms.2015.50960 7 RCTs, n = 280 · LDL n.s.
Xia W et al. (2020). The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile. Pharmacol Res 161:105113. 10.1016/j.phrs.2020.105113 14 RCTs · LDL n.s.
Fornari Laurindo L et al. (2025). Assessing the effects of moderate to high dosage of astaxanthin supplementation. Pharmaceuticals 18(8):1097. 10.3390/ph18081097 Meta-analysis · LDL n.s., TG/HDL significant
Yoshida H et al. (2010). Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin. Atherosclerosis 209(2):520–523. 10.1016/j.atherosclerosis.2009.10.012 RCT n = 61 · LDL unchanged at 6/12/18 mg
Maki KC et al. (2015). Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food. Prostaglandins Leukot Essent Fatty Acids 99:41–46. 10.1016/j.plefa.2015.05.002 RCT n = 102 · no advantage over placebo
EFSA (2009). Scientific opinion on the substantiation of health claims related to astaxanthin. EFSA Journal 7(9):1253. 10.2903/j.efsa.2009.1253 · EFSA (2020). Safety of astaxanthin. EFSA Journal 18(2):5993. 10.2903/j.efsa.2020.5993 Regulatory assessment · claims rejected · 8 mg/day safe
Simental-Mendía LE et al. (2017). Effect of magnesium supplementation on lipid profile. Eur J Clin Pharmacol 73(5):525–536. 10.1007/s00228-017-2212-8 Meta-analysis of RCTs
Wang H et al. (2012). Influence of vitamin D supplementation on plasma lipid profiles. Lipids Health Dis 11:42. 10.1186/1476-511X-11-42 12 RCTs
Osadnik T et al. (2022). A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res 183:106402. 10.1016/j.phrs.2022.106402 Network meta-analysis, 131 studies · policosanol, bergamot
Ried K et al. (2013). Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev 71(5):282–299. 10.1111/nure.12012 Meta-analysis
Khoo YS, Aziz Z (2009). Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 34(2):133–145. 10.1111/j.1365-2710.2008.00998.x Meta-analysis · null finding
Dehzad MJ et al. (2023). Effects of curcumin/turmeric supplementation on lipid profile. Complement Ther Med 75:102955. 10.1016/j.ctim.2023.102955 Meta-analysis · GRADE low
Xu R et al. (2020). Effect of green tea consumption on blood lipids. Nutr J 19:48. 10.1186/s12937-020-00557-5 Meta-analysis of RCTs
Wider B et al. (2013). Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev 3:CD003335. 10.1002/14651858.CD003335.pub3 3 RCTs, n = 262
Laffin LJ et al. (2023). Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers (SPORT). J Am Coll Cardiol 81(1):1–12. 10.1016/j.jacc.2022.10.013 RCT n = 190, 28 days · without ASCVD · funded by AstraZeneca
Martí-Carvajal AJ et al. (2017). Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 8:CD006612. 10.1002/14651858.CD006612.pub5 15 RCTs, n = 71,422
Obeid R et al. (2025). Circulating trimethylamine N-oxide and cardiovascular, cerebral, and renal diseases including mortality: umbrella review. Nutr Metab Cardiovasc Dis 35(8):103908. 10.1016/j.numecd.2025.103908 Umbrella review, 27 meta-analyses · confidence "critically low"
Cannon CP et al. (2015). Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). NEJM 372(25):2387–2397. 10.1056/NEJMoa1410489 RCT
Sabatine MS et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). NEJM 376(18):1713–1722. 10.1056/NEJMoa1615664 RCT
Schwartz GG et al. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). NEJM 379(22):2097–2107. 10.1056/NEJMoa1801174 RCT
Nissen SE et al. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). NEJM 388(15):1353–1364. 10.1056/NEJMoa2215024 RCT · MACE HR 0.87
Ray KK et al. (2020). Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10/11). NEJM 382(16):1507–1519. 10.1056/NEJMoa1912387 RCTs · LDL lowering proven, outcomes pending
Koch CA et al. (2023). Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials. Eur Heart J 44(28):2609–2622. 10.1093/eurheartj/ehad211 30 RCTs · adults, mixed health status · LDL −0.30 mmol/L, ApoB −12.9 mg/dL
Wang F et al. (2015). Effects of vegetarian diets on blood lipids. J Am Heart Assoc 4(10):e002408. 10.1161/JAHA.115.002408 11 RCTs · LDL −0.34 mmol/L, HDL −0.10 mmol/L, TG n.s.
Termannsen AD et al. (2022). Effects of vegan diets on cardiometabolic health. Obes Rev 23(9):e13462. 10.1111/obr.13462 11 RCTs, n = 796 · overweight/type 2 diabetes · LDL −0.24 mmol/L
Meng H et al. (2020). Effects of intermittent fasting and energy-restricted diets on lipid profile. Nutrition 77:110801. 10.1016/j.nut.2020.110801 34 studies · compared with no diet · LDL −6.2 mg/dL
Cioffi I et al. (2018). Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes. J Transl Med 16(1):371. 10.1186/s12967-018-1748-4 11 RCTs · same result as continuous calorie restriction
Liu D et al. (2022). Calorie restriction with or without time-restricted eating in weight loss. NEJM 386(16):1495–1504. 10.1056/NEJMoa2114833 RCT n = 139, 12 months · obesity · eating window adds no effect
Patikorn C et al. (2021). Intermittent fasting and obesity-related health outcomes: an umbrella review. JAMA Netw Open 4(12):e2139558. 10.1001/jamanetworkopen.2021.39558 11 meta-analyses, 130 RCTs · 93 % of findings low or very low quality of evidence
Bueno NB et al. (2013). Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss. Br J Nutr 110(7):1178–1187. 10.1017/S0007114513000548 13 RCTs ≥ 12 months · obesity · LDL +0.12 mmol/L
Joo M et al. (2023). Effects of very low-carbohydrate ketogenic diets on lipid profiles in normal-weight adults. Nutr Rev 81(11):1393–1401. 10.1093/nutrit/nuad017 3 RCTs · normal weight · LDL +1.08 mmol/L, ApoB +0.35 g/L · small data base
Chandola T, Brunner E, Marmot M (2006). Chronic stress at work and the metabolic syndrome: prospective study. BMJ 332(7540):521–525. 10.1136/bmj.38693.435301.80 Whitehall II cohort, n = 10,308, 14 years · observational · OR 2.25 for metabolic syndrome
Catalina-Romero C et al. (2013). The relationship between job stress and dyslipidemia. Scand J Public Health 41(2):142–149. 10.1177/1403494812470400 Cross-sectional, n = 91,593 employees · elevated LDL OR 1.14
Tenk J et al. (2018). Perceived stress correlates with visceral obesity and lipid parameters of the metabolic syndrome. Psychoneuroendocrinology 95:63–73. 10.1016/j.psyneuen.2018.05.014 Meta-analysis, 17 observational studies · TG +7.5, HDL −1.7 mg/dL
Scott-Sheldon LAJ et al. (2020). Mindfulness-based interventions for adults with cardiovascular disease. Ann Behav Med 54(1):67–73. 10.1093/abm/kaz020 Meta-analysis, 16 studies, n = 1,476 · CHD patients · blood pressure and mental health improved, lipids not reported
Guasch-Ferré M et al. (2022). Consumption of olive oil and risk of total and cause-specific mortality among U.S. adults. J Am Coll Cardiol 79(2):101–112. 10.1016/j.jacc.2021.10.041 Cohorts n = 92,383, 28 years · observational
Martínez-González MA et al. (2022). Olive oil consumption and cardiovascular risk. Clin Nutr 41(12):2659–2682. 10.1016/j.clnu.2022.10.001 Meta-analysis, 24 cohorts + 1 RCT, n = 806,203
Jabbarzadeh-Ganjeh B et al. (2023). The effects of olive oil consumption on blood lipids. Br J Nutr 130(4):728–736. 10.1017/S0007114522003683 34 RCTs · LDL ±0
Hollænder PL et al. (2015). Whole-grain and blood lipid changes in apparently healthy adults. Am J Clin Nutr 102(3):556–572. 10.3945/ajcn.115.109165 24 RCTs · LDL −0.09 mmol/L
Aune D et al. (2016). Whole grain consumption and risk of cardiovascular disease, cancer, and all cause mortality. BMJ 353:i2716. 10.1136/bmj.i2716 45 cohorts · observational
Pan A et al. (2009). Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr 90(2):288–297. 10.3945/ajcn.2009.27469 28 RCTs · whole seed LDL −0.16 mmol/L, flaxseed oil ±0
Li L et al. (2023). Effects of flaxseed supplementation on blood pressure. Food Funct 14(2):675–690. 10.1039/d2fo02566c 33 RCTs, n = 2,427
Pacheco LS et al. (2022). Avocado consumption and risk of cardiovascular disease in US adults. J Am Heart Assoc 11(7):e024014. 10.1161/JAHA.121.024014 Cohorts n = 110,487 · observational
Mostafazadeh P et al. (2026). Avocado consumption and lipid profile: a meta-analysis of RCTs. Crit Rev Food Sci Nutr 66(4):780–790. 10.1080/10408398.2025.2531222 Meta-analysis of RCTs · LDL −6.2 mg/dL
Zheng J et al. (2012). Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 15(4):725–737. 10.1017/S1368980011002254 17 cohorts, n = 315,812 · observational
de Goede J et al. (2015). Effect of cheese consumption on blood lipids. Nutr Rev 73(5):259–275. 10.1093/nutrit/nuu060 5 RCTs · cheese vs. butter LDL −0.22 mmol/L
Brassard D et al. (2017). Comparison of the impact of SFAs from cheese and butter on cardiometabolic risk factors. Am J Clin Nutr 105(4):800–809. 10.3945/ajcn.116.150300 Crossover RCT n = 92 · abdominal fat, low HDL
Bechthold A et al. (2019). Food groups and risk of coronary heart disease, stroke and heart failure. Crit Rev Food Sci Nutr 59(7):1071–1090. 10.1080/10408398.2017.1392288 Cohort meta-analysis · processed meat RR 1.27 per 50 g
Zeraatkar D et al. (2019). Red and processed meat consumption and risk for all-cause mortality and cardiometabolic outcomes. Ann Intern Med 171(10):703–710. 10.7326/M19-0655 55 cohorts, > 4 million · low-certainty evidence
Lane MM et al. (2024). Ultra-processed food exposure and adverse health outcomes: umbrella review. BMJ 384:e077310. 10.1136/bmj-2023-077310 45 pooled analyses, n ≈ 9.9 million · GRADE very low
Aune D et al. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality. Int J Epidemiol 46(3):1029–1056. 10.1093/ije/dyw319 95 cohorts · observational
Neal B et al. (2021). Effect of salt substitution on cardiovascular events and death (SSaSS). NEJM 385(12):1067–1077. 10.1056/NEJMoa2105675 Cluster RCT n = 20,995 · rural China, mean age 65, high risk
Yin X et al. (2022). Effects of salt substitutes on clinical outcomes. Heart 108(20):1608–1615. 10.1136/heartjnl-2022-321332 21 RCTs, n = 31,949 · blood pressure −4.6/−1.6 mmHg
Ziaei R et al. (2021). The effect of probiotic fermented milk products on blood lipid concentrations. Nutr Metab Cardiovasc Dis 31(4):997–1015. 10.1016/j.numecd.2020.12.023 39 RCTs, n = 2,237 · LDL −7.3 mg/dL
Wu Y et al. (2017). Effect of Lactobacillus on blood lipid profile. PLoS One 12(6):e0178868. 10.1371/journal.pone.0178868 15 RCTs, n = 976 · LDL −0.23 mmol/L
Liu G et al. (2014). Effects of tea intake on blood pressure. Br J Nutr 112(7):1043–1054. 10.1017/S0007114514001731 25 RCTs, n = 1,476
Ellis LR et al. (2022). Effects of Hibiscus sabdariffa on cardiovascular risk markers. Nutr Rev 80(6):1723–1737. 10.1093/nutrit/nuab104 17 RCTs · high heterogeneity
Sahebkar A et al. (2017). Effects of pomegranate juice on blood pressure. Pharmacol Res 115:149–161. 10.1016/j.phrs.2016.11.018 8 RCTs
Cheng W et al. (2025). Pomegranate and lipid profile: a meta-analysis of RCTs. Prostaglandins Other Lipid Mediat 178:106992. 10.1016/j.prostaglandins.2025.106992 37 RCTs, n = 2,695 · LDL n.s.
Hadi A et al. (2021). The effect of apple cider vinegar on lipid profiles and glycemic parameters. BMC Complement Med Ther 21(1):179. 10.1186/s12906-021-03351-w 9 studies · LDL n.s.
Sarmadi B et al. (2023). Effect of cinnamon on lipid profile: an umbrella review. Nutr Metab Cardiovasc Dis 33(10):1821–1835. 10.1016/j.numecd.2023.03.010 11 meta-analyses · LDL −0.8 mg/dL
Fateh HL et al. (2024). Chia seed supplementation and cardiometabolic risk factors. Prostaglandins Other Lipid Mediat 175:106907. 10.1016/j.prostaglandins.2024.106907 14 RCTs, n = 835 · LDL only at high dose
Bhatt DL et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). NEJM 380(1):11–22. 10.1056/NEJMoa1812792 RCT n = 8,179 · high risk, on statin · HR 0.75
Nicholls SJ et al. (2020). Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (STRENGTH). JAMA 324(22):2268–2280. 10.1001/jama.2020.22258 RCT n = 13,078 · HR 0.99
Manson JE et al. (2019). Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). NEJM 380(1):23–32. 10.1056/NEJMoa1811403 RCT n = 25,871 · general population · HR 0.92 (n.s.)
Gencer B et al. (2021). Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation. Circulation 144(25):1981–1990. 10.1161/CIRCULATIONAHA.121.055654 7 RCTs, n = 81,210 · HR 1.25; > 1 g/day HR 1.49
Bjelakovic G et al. (2012). Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 3:CD007176. 10.1002/14651858.CD007176.pub2 78 RCTs, n = 296,707 · mortality RR 1.04
Myung SK et al. (2013). Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease. BMJ 346:f10. 10.1136/bmj.f10 50 RCTs, n = 294,478 · RR 1.00
Sesso HD et al. (2012). Multivitamins in the prevention of cardiovascular disease in men (Physicians' Health Study II). JAMA 308(17):1751–1760. 10.1001/jama.2012.14805 RCT n = 14,641, 11 years · HR 1.01
Ried K (2016). Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity. J Nutr 146(2):389S–396S. 10.3945/jn.114.202192 20 RCTs, n = 970 · author funded by a manufacturer
Hodis HN et al. (2021). Nattokinase atherothrombotic prevention study. Clin Hemorheol Microcirc 78(4):339–353. 10.3233/CH-211147 RCT n = 265, 3 years · no effect
Sahebkar A et al. (2015). Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors. Int J Cardiol 189:47–55. 10.1016/j.ijcard.2015.04.008 10 RCTs · HDL −4.2 mg/dL
Chen F et al. (2024). Effects of nicotinamide mononucleotide supplementation on glucose and lipid metabolism. Curr Diab Rep 25(1):4. 10.1007/s11892-024-01557-z 8 RCTs, n = 342 · no effect
Shiraseb F et al. (2022). Effect of L-arginine supplementation on blood pressure in adults. Adv Nutr 13(4):1226–1242. 10.1093/advances/nmab155 22 RCTs · SBP −6.4 mmHg
Schulman SP et al. (2006). L-arginine therapy in acute myocardial infarction (VINTAGE MI). JAMA 295(1):58–64. 10.1001/jama.295.1.58 RCT · stopped because of deaths
Mirenayat MS et al. (2018). Effect of L-citrulline supplementation on blood pressure. Curr Hypertens Rep 20(11):98. 10.1007/s11906-018-0898-3 5 studies · n.s.
Holubarsch CJ et al. (2008). The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure (SPICE). Eur J Heart Fail 10(12):1255–1263. 10.1016/j.ejheart.2008.10.004 RCT n = 2,681 · HR 0.95 (n.s.)
Razmpoosh E et al. (2022). The effect of olive leaf extract on cardiovascular health markers. Diabetol Metab Syndr 14(1):151. 10.1186/s13098-022-00920-y 12 studies, n = 819
Brown PDS et al. (2023). Emblica officinalis (amla) and lipid profile: a meta-analysis. BMC Complement Med Ther 23(1):190. 10.1186/s12906-023-03997-8 9 RCTs, n = 535 · prediction interval −48 to +18
Khodamoradi K et al. (2020). The effects of fenugreek on cardiometabolic risk factors. Complement Ther Med 52:102416. 10.1016/j.ctim.2020.102416 12 studies · mostly people with diabetes
Salih AK et al. (2023). The effect of ginger supplementation on lipid profile. Phytother Res 37(6):2472–2483. 10.1002/ptr.7769 Meta-analysis · LDL n.s.
Rahnama I et al. (2023). The effect of Spirulina supplementation on lipid profile. Pharmacol Res 193:106802. 10.1016/j.phrs.2023.106802 20 studies, n = 1,076
Huang H et al. (2020). Effects of quercetin supplementation on blood pressure and lipid profile. Nutr Rev 78(8):615–626. 10.1093/nutrit/nuz071 17 RCTs, n = 896 · lipids unchanged
Tzang CC et al. (2024). The impact of taurine on blood pressure and heart rate. Nutr J 23(1):93. 10.1186/s12937-024-00995-5 20 RCTs, n = 808
Vajdi M et al. (2023). Chromium supplementation and lipid profile: an umbrella review. Biol Trace Elem Res 201(8):3658–3669. 10.1007/s12011-022-03474-2 8 meta-analyses · no effect
Stranges S et al. (2007). Effects of long-term selenium supplementation on the incidence of type 2 diabetes. Ann Intern Med 147(4):217–223. 10.7326/0003-4819-147-4-200708210-00175 RCT · diabetes HR 1.55
Hur MH et al. (2012). Aromatherapy for treatment of hypertension: a systematic review. J Eval Clin Pract 18(1):37–41. 10.1111/j.1365-2753.2010.01521.x 1 RCT + 4 non-randomized studies · unconvincing
Dujic G et al. (2024). Effects of orally administered cannabidiol on blood pressure in hypertension. Cannabis Cannabinoid Res 9(4):979–989. 10.1089/can.2022.0320 Crossover RCT n = 70
Jalili Z et al. (2023). Effects of collagen peptide supplementation on cardiovascular markers. Br J Nutr 129(5):779–794. 10.1017/S0007114522001301 12 RCTs · I² 93–99 %
Hadi A et al. (2019). Effects of melatonin supplementation on blood pressure. Horm Metab Res 51(3):157–164. 10.1055/a-0841-6638 5 RCTs
Ursoniu S et al. (2017). Lipid-modifying effects of krill oil in humans. Nutr Rev 75(5):361–373. 10.1093/nutrit/nuw063 7 RCTs, n = 662
Lu Z et al. (2008). Effect of Xuezhikang on cardiovascular events and mortality in patients with previous myocardial infarction (CCSPS). Am J Cardiol 101(12):1689–1693. 10.1016/j.amjcard.2008.02.056 RCT ≈ 5,000 post-infarction patients · red yeast rice extract
Wu T et al. (2008). Danshen for acute myocardial infarction. Cochrane Database Syst Rev 2:CD004465. 10.1002/14651858.CD004465.pub2 only 1 true RCT · evidence insufficient
Banach M et al. (2023). The association between daily step count and all-cause and cardiovascular mortality. Eur J Prev Cardiol 30(18):1975–1985. 10.1093/eurjpc/zwad229 17 cohorts, n = 226,889 · observational
Paluch AE et al. (2023). Prospective association of daily steps with cardiovascular disease. Circulation 147(2):122–131. 10.1161/CIRCULATIONAHA.122.061288 8 cohorts, n = 20,152 · under age 60 not significant
Kodama S et al. (2009). Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women. JAMA 301(19):2024–2035. 10.1001/jama.2009.681 33 cohorts, n = 102,980 · healthy general population
Mandsager K et al. (2018). Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 1(6):e183605. 10.1001/jamanetworkopen.2018.3605 Cohort n = 122,007 · clinically referred patients
Leong DP et al. (2015). Prognostic value of grip strength (PURE). Lancet 386(9990):266–273. 10.1016/S0140-6736(14)62000-6 Cohort n = 139,691, 17 countries, ages 35–70
Poon ETC et al. (2024). High-intensity interval training for cardiometabolic health in adults with metabolic syndrome. Br J Sports Med 58(21):1267–1284. 10.1136/bjsports-2024-108481 23 RCTs, n = 1,374 · metabolic syndrome · HIIT = moderate training
Fu Y et al. (2017). Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea. Sleep Breath 21(1):181–189. 10.1007/s11325-016-1393-1 27 cohorts · severe OSA HR 2.73
Sánchez-de-la-Torre M et al. (2023). Adherence to CPAP treatment and the risk of recurrent cardiovascular events. JAMA 330(13):1255–1265. 10.1001/jama.2023.17465 IPD meta-analysis, 3 RCTs, n = 4,186 · secondary prevention · ≥ 4 h/night HR 0.69
Valtorta NK et al. (2016). Loneliness and social isolation as risk factors for coronary heart disease and stroke. Heart 102(13):1009–1016. 10.1136/heartjnl-2015-308790 Longitudinal meta-analysis · observational
Harshfield EL et al. (2020). Association between depressive symptoms and incident cardiovascular diseases. JAMA 324(23):2396–2405. 10.1001/jama.2020.23068 22 cohorts, n = 563,255 · HR 1.06–1.10
Tully PJ et al. (2021). Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 12:CD008012. 10.1002/14651858.CD008012.pub4 37 RCTs · event evidence very uncertain
Larvin H et al. (2021). Risk of incident cardiovascular disease in people with periodontal disease. Clin Exp Dent Res 7(1):109–122. 10.1002/cre2.336 30 cohorts · RR 1.20
Luo Y et al. (2021). Periodontal therapy for blood pressure in people with hypertension. Cochrane Database Syst Rev 12:CD009409. 10.1002/14651858.CD009409.pub2 8 RCTs · BP effect unproven
van Kempen E et al. (2018). WHO environmental noise guidelines: systematic review on environmental noise and cardiovascular and metabolic effects. Int J Environ Res Public Health 15(2):379. 10.3390/ijerph15020379 WHO review · IHD RR 1.08 per 10 dB, GRADE high
Jdidi H et al. (2024). The effects of cold exposure on cardiovascular variables: a meta-analysis. J Therm Biol 121:103857. 10.1016/j.jtherbio.2024.103857 24 acute studies · healthy people
Wu Y et al. (2019). Yoga as antihypertensive lifestyle therapy. Mayo Clin Proc 94(3):432–446. 10.1016/j.mayocp.2018.09.023 49 studies, n = 3,517, mean age 49
Li X et al. (2024). Effect of Tai Chi vs aerobic exercise on blood pressure in patients with prehypertension. JAMA Netw Open 7(2):e2354937. 10.1001/jamanetworkopen.2023.54937 RCT n = 342, 12 months, mean age 49
Chaddha A et al. (2019). Device and non-device-guided slow breathing to reduce blood pressure. Complement Ther Med 45:179–184. 10.1016/j.ctim.2019.03.005 17 RCTs · SBP −5.6 mmHg
Lee EKP et al. (2020). Effect of mindfulness-based interventions on blood pressure. Hypertension 76(6):1992–2001. 10.1161/HYPERTENSIONAHA.120.16160 12 RCTs · 24-h BP n.s.
Edwards JJ et al. (2023). Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis. Br J Sports Med 57(20):1317–1326. 10.1136/bjsports-2022-106503 270 RCTs, n = 15,827 · isometric −8.2/−4.0 mmHg
Torquati L et al. (2018). Shift work and the risk of cardiovascular disease. Scand J Work Environ Health 44(3):229–238. 10.5271/sjweh.3700 21 studies, n = 173,010 · observational
Behrouzi B et al. (2022). Association of influenza vaccination with cardiovascular risk. JAMA Netw Open 5(4):e228873. 10.1001/jamanetworkopen.2022.8873 6 RCTs, n = 9,001 · effective only in people with heart disease
US Preventive Services Task Force (2022). Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons. JAMA 328(17):1740–1746. 10.1001/jama.2022.18625 Guideline · recommends against use for prevention
Liu XX et al. (2022). Green space and cardiovascular disease: a systematic review with meta-analysis. Environ Pollut 301:118990. 10.1016/j.envpol.2022.118990 53 studies · observational
Ahmadi MN et al. (2024). Device-measured stationary behaviour and cardiovascular and orthostatic circulatory disease incidence. Int J Epidemiol 53(6):dyae136. 10.1093/ije/dyae136 UK Biobank n = 83,013 · standing time without CVD benefit
Ekelund U et al. (2019). Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality. BMJ 366:l4570. 10.1136/bmj.l4570 8 cohorts, n = 36,383, mean age 63
Zou H et al. (2019). Association between weight cycling and risk of developing cardiovascular disease, hypertension, or diabetes mellitus. Front Endocrinol 10:728. 10.3389/fendo.2019.00728 23 cohorts, n = 441,199 · observational, confounding possible
Chaput JP et al. (2025). Sleep regularity and major adverse cardiovascular events. J Epidemiol Community Health 79(4):257–264. 10.1136/jech-2024-222795 UK Biobank n = 72,269, ages 40–79 · HR 1.26
Windred DP et al. (2024). Sleep regularity is a stronger predictor of mortality risk than sleep duration. Sleep 47(1):zsad253. 10.1093/sleep/zsad253 UK Biobank n = 60,977
Nikbakhtian S et al. (2021). Accelerometer-derived sleep onset timing and cardiovascular disease incidence. Eur Heart J Digit Health 2(4):658–666. 10.1093/ehjdh/ztab088 n = 103,712 · sleep onset 10–11 p.m.
Estruch R et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). NEJM 378(25):e34. 10.1056/NEJMoa1800389 RCT n = 7,447, ages 55–80, high risk · corrected and republished in 2018
Rees K et al. (2019). Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 3:CD009825. 10.1002/14651858.CD009825.pub3 30 RCTs, n = 12,461 · LDL small, blood pressure −3/−2
Sesso HD et al. (2022). Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events (COSMOS). Am J Clin Nutr 115(6):1490–1500. 10.1093/ajcn/nqac055 RCT n = 21,442, age ≥ 60 · total CVD n.s., CV death HR 0.73 (secondary endpoint)
Reynolds A et al. (2019). Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet 393(10170):434–445. 10.1016/S0140-6736(18)31809-9 185 cohorts + 58 RCTs · optimum 25–29 g/day · GRADE moderate
Juraschek SP et al. (2012). Effects of vitamin C supplementation on blood pressure. Am J Clin Nutr 95(5):1079–1088. 10.3945/ajcn.111.027995 29 small RCTs, 8 weeks · SBP −3.8 mmHg
Liu Z et al. (2023). Effects of coenzyme Q10 supplementation on lipid profiles in adults: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 108(1):232–249. 10.1210/clinem/dgac585 50 RCTs, n = 2,794 · LDL −3.0 mg/dL, TG −9.1 mg/dL
Shimizu M et al. (2015). Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS One 10(10):e0139795. 10.1371/journal.pone.0139795 11 RCTs · LDL −0.22 mmol/L
European Commission (2026). Summary report of the meeting of the Standing Committee on Plants, Animals, Food and Feed (SCoPAFF), Section General Food Law, May 13, 2026. food.ec.europa.eu Meeting minutes · vote on the monacolin ban
Verordnung (EU) Nr. 1160/2011 der Kommission [Commission Regulation (EU) No 1160/2011: authorized disease-risk-reduction claim for beta-glucans from oats]. EUR-Lex 32011R1160 EU regulation
Max Rubner-Institut (2026). Wissenschaftliche Einordnung: Ballaststoffe [Scientific assessment: dietary fiber]. As of June 2026; intake data from the German National Nutrition Survey II (Nationale Verzehrsstudie II). mri.bund.de German federal research institute · median 18 g (women), 19 g (men)
World Health Organization (2025). Use of lower-sodium salt substitutes: WHO guideline. Geneva: WHO. iris.who.int Guideline · conditional recommendation; caution with kidney disease and potassium-sparing diuretics
Grundy SM et al. (2019). 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol. Circulation 139(25):e1082–e1143. 10.1161/CIR.0000000000000625 Guideline · ezetimibe added to a statin
Micha R, Wallace SK, Mozaffarian D (2010). Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus. Circulation 121(21):2271–2283. 10.1161/CIRCULATIONAHA.109.924977 Meta-analysis, 20 studies · nutrient comparison processed vs. unprocessed meat
Statistisches Bundesamt (2025). Todesursachenstatistik 2024 [German Federal Statistical Office, cause-of-death statistics 2024]: around 339,000 deaths from cardiovascular disease out of roughly 1.01 million deaths in total. destatis.de · causes of death Official statistics

A note on context: All effect sizes are averages from study populations – your own response can differ, especially for dietary cholesterol and exercise. Most of the nutrition studies come from the general population or from people with elevated values; the movement studies on sitting and walking after meals were done in young healthy adults, and the diet-versus-exercise comparisons in overweight participants. Cohort studies (eggs, sauna, particulate matter, sleep) show associations; the causal statements rest on randomized trials and Mendelian randomization. The order of the ranking is my professional weighting; the effect sizes behind it are documented. This document is educational and replaces neither diagnosis nor treatment. Discuss any change to ongoing medication with your doctor.